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RÉSUMÉ 
Cette étude vise à déterminer le montant des dépenses publiques allouées à la 
prévention, au traitement, aux soins et aux services reliés au VIH en Iran en 2004. 
Depuis 1987, l'épidémie du VIH en Iran s'est transformée d'une épidémie de faible 
niveau à une de niveau important (concentrated epidemic). Les dépenses reliées au 
VIH en Iran peuvent être catégorisées en sept programmes: les soins ambulatoires, 
les hospitalisations, les médicaments antirétroviraux, les tests sanguins et le 
dépistage, l'éducation de la population, la réduction des méfaits ainsi que le 
contrôle du VIH dans les forces armées. 
Les coûts pour les hospitalisations et les soins ambulatoires ont été estimés par 
l'agrégation des dépenses de niveau micro (bottom-up approach). Les dépenses 
associées aux cinq autres programmes ont été estimées à partir des coûts macro 
(top-down approach). Les dépenses totales estimées en 2004 sont de 
12841 974 $US. L'analyse de sensibilité indique que le montant de ces dépenses 
pourraient se situer entre Il 058967 $US et 20381 000 $US. 
Cette étude recommande, entre autres, que l'Iran améliore les systèmes 
d'informations médicales de ses établissements de santé. Un système de suivi et 
d'évaluation commun à plusieurs sites, collectant des données de façon prospective 
et systématique permettrait d'améliorer la gestion des patients ainsi que le suivi et 
l'évaluation des services de santé. 
Mots clés : VIH, SIDA, coûts, dépenses, Iran, soins ambulatoires, hospitalisation, 
soins, prévention, services d'éducation, suivi, évaluation. 
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ABSTRACT 
The main objective of the current study was to detennine public expenditures on 
HIV prevention, treatment, care, and support services in Iran in 2004. Since 1987, 
the HIV epidemic in Iran has extended itself and changed from a low level to a 
concentrated epidemic. The total country expenditure are as on HIV in Iran in 2004 
comprised seven main programs including inpatient care, outpatient care, provision 
of antiretroviral drugs (ART), blood testing and screening, public education, hann 
reduction, and anned forces HIV control. 
U sing a bottom-up approach we estimated inpatient and outpatient costs and used 
them as a proxy for estimating national expenditure on treatment and care. The 5 
other areas of expenditure were estimated using a top-down approach. 
Total expenditures for the 7 programs were estimated to be 12 841 974 US $.Based 
on the sensitivity analyses, the lower and upper limit of direct public medical 
expenditures on HIV ranged between Il 058 967 US$ and 20 381 000 US$, 
respectively in Iran in 2004. 
One of the 15 recommendations presented in this report is that Iran needs to 
improve medical record systems in health facilities. This might be aided by setting 
up a multi-center prospective monitoring and evaluation system with data gathered 
systematically in health facilities collecting infonnation to improve patient 
management and health service monitoring and evaluation. 
Key words: HIV, AIDS, cost, expenditure, Iran, outpatient, inpatient, care, 
prevention, educational services, monitoring, evaluation. 
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INTRODUCTION 
According to Ul'lJ"AIDS 2006 report on the global AIDS epidemic, important 
progress has been seen in tackling the HIV epidemic in recent years, but in many 
countries the epidemic continues to outpace local responses, with HIV new 
infections continuing to increase in certain regions and countries (UNAIDS, 2006). 
An estimated 39, 6 (33, 4 - 46) million people lived with HIV worldwide in 
2005(UNAIDS, 2006). Approximate1y 4,1 million people became newly infected 
with HIV, while approximately 2,9 million people died of AIDS-related illnesses in 
2005. In the key area of financia1 resources, the 8,3 billion US $ availab1e for the 
AIDS response in 2005 is more than five times the funding available in 2001, and is 
currently well within the Declaration of Commitment target range (Declaration of 
Commitment on HIV/AIDS,2001). Global resources for the AIDS response have 
grown from 1,6 billion US$ in 2001 to 8,3 billion US$ in 2005, a significant 
increase that highlights the need to coordinate, monitor and evaluate spending to 
ensure maximum impact for people in need ( UNAIDS, 2006). In addition to donor 
funding, domestic public expenditure in heavily impacted countries grew to 2,5 
billion US$ in 2005. At the same time, the report notes that the funding gap 
continues to increase and it is estimated that over 22,1 billion US$ will be needed 
annually as from 2008 (UNAIDS 2006). 
In an encouraging deve1opment, six of Il African countries reported declines of 
25% or more in HIV prevalence among 15-24 year-olds in capital cities. Rates of 
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sex among young people declined in nine of 14 sub-Saharan countries. Condom use 
with a non-regular partner increased in eight out of Il sub-Saharan countries, 
although overall use of condoms remains below 50%. Use of HIV testing and 
counseling, an important tool for facilitating both treatment and prevention, 
quadrupled to 16,5 million people tested in 2005 ( UNAIDS, 2006). Fifty eight 
countries reported that 74% of primary schools and 81 % of secondary schools now 
provide HIV education. While this progress is notable, the HIV prevention 
response falls short in many areas. The 2001 Declaration of Commitment calls for 
90% of young people to be knowledgeable about AIDS by 2005, yet sU1yeys 
indicate that fewer than 50% of young people achieved comprehensive knowledge 
levels. An area of exceptional concern is the ongoing shortfall in care to prevent 
mother-to-child HIV infection, in which just 9% of pregnant women were covered 
(UNAIDS, 2006). 
From 1987 till present, the HIV epidemic in Iran has changed froni a low level 
epidemic, with no population group having a prevalence greater than 5%, to a 
concentrated epidemic. In a concentrated epidemic, the prevalence among pregnant 
women is below 1 % in urban areas, but sorne most at risk groups have prevalence 
rates greater than 5%. A cumulative figure of 4846 reported HIV infected people 
were officially recorded by the end of 2002 but the real number of people living 
with HIV (PLHIV) in Iran was estimàted to be around 20 000 in that year (Iran 
Ministry of Health, CDC report, 2003).The number of PLHIV in Iran was 
'estimated to have increased from 37 000 in 2003, to 66 000 (36 000-160 000) in 
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2005. These figures, however, are considered to be underestimates of the real 
number of people living with HIV in Iran (UNAIDS 2006). 
ln Iran, HIV infection affects different populations including injection drug users 
(IDUs), sexually active men and women, children of HIV positive women, and 
recipients of infected blood and blood products. The increasing number of HIV 
infected people, has resulted in increasing number of people requiring the use of 
health and social services. The HIV epidemic in Iran affects individuals, their 
families, and Iranian society as a whole. Although not a generalized health and 
development crisis so far, the epidemic may jeopardize the society and pose even 
greater and more severe hazards for the future. 
The first person infected with HIV in Iran was diagnosed in 1987. The probable 
transmission mode was through contaminated blood transfusion. The epidemic that 
happened in a prison in 1995 attracted govemment's attention to the problem of 
HIV in the country, which was due to needle sharing (Country Report on UNGASS 
Declaration of Commitment, 2006). From than on, planning for HIV prevention 
and care has entered a new phase and nowadays HIV prevention, treatment, care, 
and support services are in the pilot phase to being integrated into the primary 
health care system of Iran. 
The Voluntary Counseling and Testing (VCT) centers established in 1999 started 
with providing voluntary counseling and testing of HIV positive people and their 
families and included worried HIV negative people who would refer them. Sorne 
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centers subsequently started providing outpatient antiretroviral therapy for patients 
from 1997 and was revised in 2004.Triangular Clinics were also established, which 
focus on 3 important issues that are tightly related to each other including HIV, 
other Sexually Transmitted Diseases, and IDUs. Finally, in 2002 Harm Reduction 
centers, and in 2003 'Drop-in centers and outreach services for IDUs were 
established (Iran Ministry of Health, 2006). Most of the earlier established 'VCT 
centers' now also provide sorne HIV-related outpatient services that overlap with 
the Triangular Clinics. Sorne of the Harm Reduction centers also started to provide 
services that overlap with the Triangular clinics. These three are mostly located in 
one place. Traditionally, most of the 'VCT centers' that provide services beyond 
the mere 'VCT' are still called 'VCTs' by the healthcare workers within the system 
and their activities are integrated with Triangular Clinics' activities. Nevertheless, 
these centers essentially provide HIV outpatient services, and hence we have 
retained the latter term in this report. However, to maintain the commonly used 
nomenclature of 'VCT center' with the health system, the term 'VCT center' or 
'VCT' is used interchangeably, given the fact that the providers describe their 
centers as such . 
Assessing the success of these programs in Iran is essential. Four criteria are often 
used to assess the success of health care provision including: efficiency, 
effectiveness, equity, and acceptability of the services. These criteria can be used to 
assess specific interventions, programs and models of care, e.g. the way service 
provision has been organized, be these preliminary hospital based, including 
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inpatient and outpatient care, or primary and community care services (Beck and 
Miners, 2001; Drummond et al., 1997). 
ln addition, relevant and accurate knowledge conceming diseases' burden, trends, 
risk factors, prevention modes, and treatment plays important role in appropriate 
decision making. With the increasing HIV case load in Iran, the need for HIV care 
services is increasing as are the resources needed. For better programme budgeting 
and resource allocation activities, the costs of HIV care in Iran needs to be 
estimated. Indeed, the decision makers need to know what resources are provided, 
what resources are needed, their costs, and the gap between available and needed 
resources. 
To provide relevant data for Iranian policy makers, a comprehensive project titled 
"Burden of HIV Infection in Iran" was designed. This project comprises 3 phases: 
Phase 1- "The public expenditures on HIV treatment, care, prevention, and support 
services in Iran in 2004" which would provide an overview about what the areas of 
HIV expenditure and monetary resources were in Iran .This study could clarify the 
next steps and the information gaps regarding use, cost, and outcome of service 
provision in Iran. 
Phase 2- A full "costing study" on HIV in Iran to estimate the costs, including 
direct and indirect costs, from both public sector and societal perspectives. This 
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phase will c1arify what resources are needed in Iran and how much these resources 
cost. 
Phase 3- Monitoring and evaluation "the effectiveness, efficiency, equity, and 
acceptability of HIV health care provision in Iran" using a longitudinal prospective 
methodology. 
For HIV service provision, it is ideal to collect data on an ongoing basis on the use 
of services, by stage and severity of HIV infection each time a patient is seen at the 
center, inc1uding information on specific opportunistic illnesses, treatment side-
effects or other illnesses. Use of services in this context inc1udes both hospital 
inpatient and outpatient services, tests and procedures performed as well the 
therapy received by these individuals. Where possible, this information should be 
combined with services received in the community or other institutions, such as 
hospices (Beck and Miners, 2001). 
The performance of cost and expenditure studies in Iran are very new and few 
studies have considered the relevant scientific and methodological issues. The 
CUITent study is the first study in the country, which addresses the cost and 
expenditure ofHIV-related service provision in Iran. 
The main areas of government expenditures on HIV service provision in 2004 were 
identified. In Iran, HIV expenditure covers the seven main programs: 
1) Inpatient care (hospitalization); 
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2) Outpatient care; 
3) Provision of antiretroviral drugs (ART); 
4) Hann reduction; 
5) Blood testing and screening; 
6) Public and school students' education. 
7) Anned forces HIV control. 
The first 4 programs are perfonned and monitored by Iranian Centre of Disease 
Control (CDC), Ministry of Health. Blood testing and screening program is 
conducted by Blood Transfusion Organization, Ministry of Health. The sixth 
pro gram is planned and perfonned by two organizations inc1uding Islamic Republic 
of Iran Broadcasting (IRIB) which provide education for all age groups and 
Ministry of Education providing education for students at pre-university levels. The 
last pro gram is run in Anny Health Care Centers with collaboration of Iran' 
Ministry of Health, CDC . 
Expenditures in each of these area were estimated to arrive at an estimation of total 
expenditure on HIV treatment, care, prevention, and support services in Iran. 
Regarding inpatient costs, we used a bottom-up approach and estimated the 
inpatient cost per individual and hospitalization. For outpatients, we estimated the 
average outpatient cost per visit. These cost estimations were used as a proxy of 
8 
inpatient and outpatient expenditures in Iran. For other areas such as public 
education, blood screening ART, harm reduction, and armed forces HIV control 
programs we focused on the expenditures with a top down approach. 
Imam Khomeini has been a university referral hospital since 1948, affiliated with 
Tehran University of Medical Sciences (TUMS). Regarding inpatient and 
outpatient's use, cost, and outcome of services, we focused on the data from Imam 
Khomeini hospital infectious disease ward and Imam Khomeini Triangular Clinic 
and VCT center which provided the most complete source of information about 
HIV in the country. We gathered additional outpatient cost data from five other 
VCTs around the country and calculated average cost per outpatient visit to 
estimate outpatient expenditures in the nationallevel. 
The study period was the year 1383 of the Iranian calendar, or from the 21 st of 
March 2004 till the 21 st March 2005 according to the Gregorian calendar. 
CHAPTERI 
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1.1. General infornlation about Iran 
Iran is situated in south-western Asia and borders the three former Soviet states, the 
Republic of Armenia, the Republic of Azerbaijan, and the Republic of 
Turkmenistan, as well as the Caspian Sea to the north, Turkey and Iraq to the west, 
the Persian Gulf and the Gulf of Oman to the south, and Pakistan and Afghanistan 
to the east. 
Iran is one of the world's largest oil rich countries and has the second largest gas 
reserves. Another special factor in Iran is that this country is a major route for drug 
trafficking, coming from neighboring Afghanistan and Pakistan, and destined for 
Europe, Central Asia and the Persian Gulf region. The large amount of drugs 
trafficked through Iran contributes to the drug problem in Iran (UNAIDS, 2005). In 
2002, Iran accounted for a quarter of world opiate seizures. At this time, it was 
officially estimated that there were between 200 000 and 300 000 drug injectors in 
the country, and this is widely regarded as an underestimate (Nissaramanesh et al, 
2005). 
With a population of 67,2 million in 2001 and a GDP of 114,1 billions US$ in 
2001, Iran is the second most populous country and the second largest economy in 
the middle-eastern region (UNAIDS, 2005). 
Iran now has a significant rate of unemployment. Although this decreased from 
14,7% in 2002 to 12% in 2004, Iran still has to create 700 000 jobs annually 
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(UNAIDS, 2005). In 2005, the unemployment rate was estimated at 12,1 % and the 
majority (70%) of the unemployed were young people under thirty (Iran CDC 
report, 2006). 
Table 1 Basic demographic and socioeconomic of Iran. 
Totat population (lhousands) 2004 69,789 
FEtmalo popula60n aged 15-24 (thou.and.) 2004 8,617 
Population aged 15-49 (thousands) 2004 39,678 
Mnllal populatioo growth rBtl! (%) 1992-2002 1.4 
% of populalion in urban atellS 2003 66,;2 
Average annual groWlh mte of uroan populaliOI1 2000-2005' 2,3 
Crvde birth rate (bi/ths per 1.000 pop,) 2004 20,8 
Cnide death rate (dEtaths per 1,OOO'pop,) 2004 5,3 
Maternai moltatlly raIe (per 100,000 liVE! b1lths) 2000 76 
Lita axpectançy al binh (yoars) 2002 69 
Total fOltility rata 2002 2.4 
Infant morlalily rata (per 1,000 live binhs) 2000 36 
Und .... 5 mortality rate (per 1,000 live births) 2000 45 
Gmss nalional inoomo, ppp, por copita (Inl.$) 2002 6,340 
Gros& dOmo&lÎc produd, par capila % growth 2001-2002 4,2 
Per caplla total exponditure on heallh (Int.S) 2001 422 
Goneral government expenditure on h"allh as % 2001 43.5 of total oJ(penditure on health 
Total adul! i1l1toracy rato 2000 24 
Adull male iIIileracy rate 2000' 17 
AduU lamale U1lleracy rate 2000 31;1 
Gross primary scMeI enrOiment ratio. mole 200til2oo1 88 
Gross prlma,y school enrOiment ralio. "'male 200012001 85 
Gr06s seeondary school enrolment ralla, male 200012001 81 
Gross se<:ondary school enrolment ralio, lemale 200012001 75 
Source: Epidemiological Fact Sheets, 2004. 
UN populaUondNision database 
UN population division databàSE> 
UN population division database 
UN pollt{tation divisiOn d.atabasè 
UN population diVisiOn database 
UN population Clivision dalabase 
UN population division dalabase 
UN population division dalabase 
WHO (WHR2004)IUNICEF 
World Hoallh Repolt 2004, WHO 
World Heallh Repolt 2004, WHO . 
World H~11h Repolt 2004; WHO 
World Heallh Report 2004, WHO 
World Bank 
WOt'ld Bank 
World Health Report 2004, WI-lO 
World Hr;>a!lh Report 2004, WHO 
UNESCO 
UNESCO 
UNESCO 
UNESCO 
UNESCO 
UNESCO 
UNESCO 
Iran's central position has made it a crossroads for migrants and it has emerged as a 
major transit area. The population is not homogeneous - although it has a Persian 
core that includes over half of the population. The Iranian population comprises 
several ethnic and linguistic groups: Persian and Persian dialects, Turkic and 
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Turkic dialects, Kurdish, Luri, Balochi, Arabic, and others. This ethnic diversity 
provides a need for especial educational and preventive plans for HIV positive and 
HIV negative groups in different provinces. 
Source: UNAIDS , 2005 
Figure 1 Ethnie groups in Iran 
x 
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Health care policy makers need to be aware of this variation in ethnie groups, 
cultures, and languages of the Iranian population, which must be taken into account 
for HIV prevention and treatment programme planning. 
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1.2. General healthcare structure and funding 
In Iran, health care is provided by both private and public sectors but the 
majority of people, especially the ones in low socioeconomic level, use the 
public health care system. Iran's "Master Health Plan", adopted in the 
1980s for the period of 1983-2000 accorded priority to basic preventive 
and curative pnmary care services as opposed to sophisticated hospital 
based tertiary care, and focused strictly on the population groups at highest 
risk, particularly in deprived areas (UNAIDS, 2005). 
A Primary Health Care network was established in Iran In 1985 and has 
evolved since then. The most peripheral service delivery points are Health 
Houses in rural areas and Health Posts in urban areas. These are supervised 
by rural and urban health centers, and the District Health Department at the 
next level. The referral system then is related to district, province, and 
tertiary level ho spi taIs (Figure 2). Healthcare service provision in each 
province. is monitored by University of Medical Sciences located in the 
same province. If there are more than one University of Medical Sciences 
in a province, the region is shared among them. For instance three Medical 
Universities are supervising health care services In Tehran provInce 
inc1uding Tehran, Shahid Beheshti, and Iran University of Medical 
Sciences. Higher medical education IS also the responsibility of the 
Universities of Medical Sciences, which aIl are supervised by the Ministry 
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of Health and Medical Education in Tehran. Integration at ServIce provider 
and user levels, and stepwise referral are the main characteristics of the 
Primary Health Care network in Iran (Shadpour, 1994).As a result of the 
prioritization and effective delivery of quality primary health care in the 
Primary Health Care network, health outcomes in rural areas are almost 
equal to those in urban areas, with outcomes in terms of infant and 
maternaI mortality nearly identical between urban and rural areas 
(UNAIDS, 2005). 
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Figure 2 Primary Health Care network in Iran 
In 2003, per capita total expenditure on health at international dollar rate was 568.5 
Int $. Per capita government expenditure on health at average exchange rate was 
6~.2 US$. Per capita government expenditure on health at international dollar rate 
was 278.5 Int$ (table II) (WHO, 2006). 
16 
Regarding funding in the health sector in 2003 and 2004, per capita total 
expenditure on health at average exchange rate was 135.2 and 157.8 US$, 
respectively (WHO, 2006). 
Table II Funding in health sector in Iran in 2003 
Total expenditure on health 6,5% of gross domestic product 
peneral government expenditure on health 10,3% of total government expenditure 
General government expenditure on health 47,3% of total expenditure on health 
Social security expenditure on health 30,9% of general government expenditure on 
health 
Social security expenditure on health 14,6% of total expenditure on health 
External resources for health such as UN 0,1% of total expenditure on health 
agencies 
Priva te expenditure on health 52,7% of total expenditure on health 
Out-of-pocket expenditure 94,8% ofprivate expenditure on health 
Private prepaid plans 4,4% of private expenditure on health 
1.3. HIV healthcare in Iran 
The CDC in Iran's Ministry of Health has several cornrnon prograrns 
regarding HIV prevention, treatrnent, care, and support in Iran. A National 
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Committee to Combat HIV, chaired by the Minister of Health, was set up 
in 1988. This Committee provides policy guidance to the National AIDS 
programme. An HIV prevention program was devised by CDC targeting 
the following populations: 
1- General population. 
2- Risky population inc1uding: 
a- Health workers and dentists; 
b-Most-at-risk groups such· as IDUs, prisoners, commercial sex 
workers, and men who have sex with men; 
3- HIV positive people and AIDS patients. 
The National Strategie HIV Plan of Iran's CDC, is based on multisectoral 
collaboration and co-ordination, and is mainly based on HIV prevention, 
care, support, and treatment services and contains the following major 
elements: 
1. Providing patients and community with information, educational 
material and communication; 
2. Serological and behavioral surveillance; 
3. Voluntary testing and counseling; 
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4. Ensuing blood safety. 
After the identification of the first case of HIV infection, Iran's national 
response to the epidemic began by the formation of the High Council on 
AIDS in 1988. In 2001 a 5-year National Strategie Plan was developed by 
the MoH together with other stakeholder institutions for the 2002-2006 
period. It was presented with the relevant executive guidelines to the 
contemporaneous government of the time. The plan emphasized the 
participation of other sectors including governmental or non governmental 
organizations. The following Il point strategy was developed to contain 
the spread ofHIV (Box 1; Iran Ministry of Health 2006): 
Box 1 Point strategies to confront with HIV in Iran, 2001 
1. Education and infonnation campaigns; 
2. Provision of safe blood supplies; 
3. Strengthening of the epidemiological care system; 
4. Strengthening of the prevention system against virus transmission at Iran's 
diagnostic, health and treatment centers; 
5. Counseling for at-risk individuals and voluntary testing for most-at -risk 
populations; 
6. Hann reduction; 
7. sn care and treatment; 
8. Counseling, care and treatment for PLHIV and their families; 
9. Strengthening and expansion of infrastructure and (financial, human and 
management) resources in an HIV related spheres; 
10. Strengthening of applied research; 
Il. Social and financial support for PLHIV, their families and individuals most-at-risk. 
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ln 2002 a document titled "Islamic Republic ofIran's Policies on HIV/AIDS" was 
compiled that inc1uded a detailed description of the country' s key national strategy . 
guidelines. Sorne of the main headings inc1ude the necessity for multi-sectorism, 
political support, accountability, leadership. and unified coordination, transparency, 
flexibility, observation of the rights of people involved, participation ·of PLHIV, 
compliance with Iranian ratified UN goals on HIV, and the final objective was the 
need for evidence-based action (Iran Ministry of Health,2006). 
Regarding public education and prevention, the government started a telephone 
counseling initiative (hot line) in 2005 and national distribution of 10 000 000 
brochures on HIV for adolescents and most-at-risk population. It is also 
considering Information-Education-Communication (IEC) interventions in public 
spaces (Ul\IAIDS, 2005). There are also TV and Radio programs to increase 
population knowledge on HIV infection. Iran Ministry of Education has also 
special plans for the education of adolescents and other pertinent age groups 
regarding HIV prevention. 
ln 2000, the government set up "Triangular Clinics" for IDUs in Kermanshah 
Province. IDU s constituent the major part of HIV positive persons in prisons and 
the first dramatic increase of cases was detected in a prison in Kermanshah 
province in 1995. Three main policies are the focal point of these c1inics. These are: 
1. Harm reduction among injecting drug users; 
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2. Treating people suffering from sexually transmitted diseases other 
than HIV; 
3. Providing treatment and psychological support for HIV positive and 
AIDS patients. 
In addition, these c1inics provide integrated services to these patients. "Triangular 
Clinics" are recognized as representing "best practice" in the Middle East and 
North Africa for controlling and preventing HIV infection. These c1inics have been 
so far established in all provinces where integrated services are being provided 
throughout the country (UNAIDS 2005). The integration of "Triangular Clinics" 
into the primary health system care of the country is now being piloted. 
Target groups of the Triangular Clinics inc1ude: 
• HIV positive people. 
• Family members of HIV positive people. 
• People who come for voluntary counseling and testing. 
• IDUs or people with a history ofhigh risk sexual contact. 
• People with Sexually Transmitted Disease (STD). 
Nowadays the outpatient HIV care sites established in 1999 play very important 
roles in HIV care provision in Iran. Outpatient services are provided by VCTs 
integrated in triangular c1inics all around the country which are established and 
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supervised by Medical Universities. Actually, each Medical University supervises a 
number of VCTs in close with the HIV Office in CDC, MoH. They provide 
voluntary counseling and testing (VCT), educational, prevention, care, and 
treatment services to the target population and more than 150 sites were established 
up to the end of 2005. Figure 3, page 23, describes the process for people coming 
for counseling and testing in VCTs. After HIV health education for general and 
most-at-risk population, sorne people are self-referred or referred to VCT centers, 
either by themselves or by a professional. These clients could be divided into 3 
groups as follow: 
1- The persons who worry about being HIV positive without any high 
risk behavior or symptom. The VCT staff detects the eligibility of 
the person based on the guidelines and if he/she is eligible to be 
tested, sends himlher for testing. People at high risk through IDU 
or multiple partners, volunteers, and STDs are eligible for HIV 
test. The test is an ELISA test antibody and is confirmed with 
Western Blot. 
If he/she IS not eligible, the VCT staff gives consultation and 
educates himlher regarding HIV and the process ends. 
2- The people who only have had a history of high risk behavior and 
might be HIV positive or HIV negative. This person will receive 
consultation and then will be tested for HIV. 
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3- The people whose test is positive. They will enter into the pro cess 
as shown in figure 4, page 24. 
If the HIV test is negative, the clients are asked to retum 6 months later to repeat 
the test. If he/she is still test negative 6 months later, he/she will enter into the 
process as shown in figure 5, page 27 they will also be consulted by a physician, or 
a specialist in infectious diseases. 
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Figure 3 Event pathway for HIV testing in Iran 
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Figure 4 Event pathway for HIV positive people refer to Triangular clinics and 
VCT centers in Iran 
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Two groups of clients receive following services at VCT centers: The HIV positive 
people (asymptomatic or symptomatic) and the families ofHIV positive people. AlI 
services are provided while maintaining strict confidentiality and security of 
personal information. For the HIV positive people, services described in Box 2 are 
generally provided: 
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Box 2 Services areplanned to be provided for HIV positive people at Triangular 
clinics and VCT centers in Iran 
• Active follow up by trained staff 
• Data registry 
• Consultation 
• Clinical and paraclinical examination considering co diseases. 
• Prophylaxis for tuberculosis, Pneumocystis Carinii Pneumonia (PCP), and 
mother to child transmission (for pregnant women) 
• Vaccination (Hepatitis B, Diphtheria-Tetanus, Pneumococcus, Influenza) 
• Drug therapy and outpatient care for people with tuberculosis, 
psychological disorders, and co-infections ( if necessary) 
• HAART including: Zidovudine, Lamivudine, and Nelfivavir, 
under the direct observation of the infectious disease specialist 
• Referring to the care delivery or supportive organs (if necessary) 
• Family planning 
• Harrn reduction organizing matched groups arnong diseased people 
• Horne care 
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From VCT centers the HW positive patients are referred to one of these 
following settings, according to necessity: 
1. Hospitals or private c1inics to be hospitalized or recelve specialist 
advice. 
2. Social support agencies such as the Iran Red Crescent Society 
(IRCS), Welfare Organization, and Imam Khomeini Help 
Committee. 
3. Hann Reduction and drug dependency treatment agencies. 
VCT staffs should also follow the referred people to be sure whether they 
are hospitalized or used the supportive activities. 
For HIV negative VCT clients, consultation and education follow a 
different path (figure 5, page 27). 
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Figure 5 HIV event pathway for HIV negative VCT clients in Iran 
1.4. Financing HIV bealtbcare in Iran 
Almost all of the HIV inpatient care services are provided by the governmental 
health sector in Iran, and almost all of the incurred costs are paid by the 
government. 
For a very small proportion of people living with HIV, inpatient care is delivered in 
the private sector hospitals. However, this amount of care is limited due to various 
reasons, including the reluctance of the private practice settings for admitting 
known HIV positive patients. Health insurance for such services is solely provided 
by governmental insurance agencies. Resources for outpatient HIV healthcare 
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services are mainly provided by the governmental sector. As HIV positive patients 
mostly prefer to refer to public clinics because all services are free of charge, the 
amount of expenditure on private health care is negligible compared with the public 
sector HIV -related expenditure. 
Foreign financial assistance by UN and international agencies constitute less than 3 
percent of total HIV healthcare-related expenditures, according to the Ministry of 
Health (Country Report on UNGASS Declaration ofCommitment, 2006). 
The last sector is the healthcare provided by lranian Non Governmental 
Organizations (NGOs) at national and subnational levels. The first HIV related 
NGO was established in 2003 in south of Tehran. In general, the NGOs provide 
preventive services and outpatient healthcare, and their financial resources are 
provided either by Iranian charities, foreign NGOs, or to a limited degree, by UN 
agencies such as UNAIDS, UNESCO or UNFP A. 
More than 95% of all HIV healthcare-related expenditure is estimated to be directly 
paid by the governmental health sector, originating from the national resources 
allocated centrally through the "Management and Planning Organization". 
The Management and Planning Organization is the highest governmental source for 
distribution of financial resources to the ministries, governmental organizations and 
institutions, and governmental health insurance agencies. The limited control of the 
Ministry of Health (MOH), inc1uding the Center for Disease Control and the 
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National HIV office, on the financial and technical activities of the Medical 
Universities at the province level affect the activities of the Medical Universities. 
They directly receive their financial resources allocated through the Management 
and Planning Organization, and their legal obligations and actual incentives for 
reporting to the MOH headquarters are therefore limited. Alternatively if financial 
resources for disease control programs allocated by Management and Planning 
Organization would be distributed by the Center for Disease Control to Medical 
Universities, this could increase the Universities' responsiveness to the Center for 
Disease Control in terms of financial and programmatic performance. 
1.5. Review of literature 
This section provides an overview of sorne of the studies done in the area of costs 
and expenditures of HIV service provision in the world with the emphasis on the 
methodology. 
1.5.1. Methodological considerations 
1.5.1.1. Designing a costing study 
There are several methodological issues that should be considered in doing studies 
on co st on HIV service provision in the country or at facility level. One important 
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point is that the researcher should have a holistic view on the context in which the 
HIV health care is provided. The context is also critical in the response to the HIV 
pandemic. 
The health systems of affected countries are inevitably at the forefront of national 
responses to the HIV pandemic. The pandemic is deeply rooted in the social and 
economic conditions within and between nations. Thus, it would be misguided to 
offer a single, simple 'recipe' for an effective response, given the importance of 
each country's context (Beck et al., 2006). 
In every costing study the research team should make decisions on the items they 
are willing to focus on. Their decision depends on: 
a) Aims of the study; 
b) Stakeholders' felt needs that prompted the research; 
c) Availability of data; and 
d) A vailability of resources. 
Cost estimates compromise direct and indirect costs. Direct costs represent the 
value of aIl goods, services, and other resources consumed in providing health care 
or dealing with side effects or other CUITent and future consequences of health care. 
Indirect costs, sometimes known as "productivity losses" include the costs of lost 
work due to absenteeism or early retirement, impaired productivity at work, and 
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lost or impaired lei sure activity. Indirect costs also include the costs of premature 
mortality (Goodman, 2004). 
The viewpoint or perspective assumed in any economlC evaluation study is 
important since an item may be a cost from one point of view ,but not a cost from 
another. Possible points of view inçlude: society, Ministry of Health, other 
government ministries, the government in general, patient, employer, the agency 
providing the pro gram and others.(Drummond et al., 1997). 
The most common viewpoints used in economic evaluations are public health 
sector and societal viewpoints. Taking a societal perspective in economlC 
evaluations leads to a higher number of cost items with a potential large impact on 
total cost estimates than in the case where the analysis is restricted to only health 
care costs (Barendregt et al ,1999 & Brouwer et al., 2001). When the analyst is in 
doubt of choosing the relevant perspective, he or she should adopts the societal 
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point of view, which is the broadest one and is al ways relevant (Drummond et al., 
1997). 
Two ways of collecting costs are either 'top down' or 'bottom up' (also called 
microcosting). Top down studies use the total budget divided by the relevant 
denominator to produce average costs per patient. This method is the quicker one 
but assumes that aIl patients have the same diagnosis, severity of illness and 
treatment. The costs produced from this method are not sensitive to changes in 
treatment. Bottom up studies measure resource use by individual patients and so are 
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able to detect treatment differences between patients. This method produces much 
better quality costs, but can be time consuming and expensive. Also top down costs 
are often available from healthcare accounting systems, whereas bottom up costs 
may need to be collected especially for that economic evaluation (Elliot and Payne, 
2005). 
Considering the context and also above mentioned issues, direct cost estimations on 
HIV service provision are mainly focused on inpatient care, outpatient visits, and 
medication provided, with sorne variations in different studies. Drummond and 
colleagues and the Canadian Coordinating Office for Heath Technology 
Assessment (CCOHTA), have recommended the direct cost estimations to be 
divided into 4 broad categories: drugs, outpatient clinical care (including physician 
and laboratory costs), inpatient hospital care and community-based home care 
(Drummond et al. 1997; Baladi, 1996). 
Rees used the co st extraction method to provide estimates of the cost of HIV 
infection to the National Health Service (NHS) in England and Wales in 1990. He 
extracted HIV costs from the global revenue cost totals of 3 NHS districts. Costs 
were broken down into AIDS inpatient and outpatient work, HIV inpatient and 
outpatient work, haemophilia work, counseling and testing, research and teaching, 
health education, drug misuse, infection control and administration (Rees, 1990). In 
another study, Mor and colleagues studied the number of outpatient visits, use of 
the emergency room, and inpatient admissions to assess the effects of 
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sociodemographic factors on health service use among people with HIV infection 
in nine communities across the US (Mor et al., 1992). Also McMurchy estimated 
the co st impact of ART for adults in Canada between 1985 and 1999.Direct costs 
included inpatient, outpatient, palliative and home-care costs, as weIl as the co st of 
ART and other medications (McMurchy,2000). 
Sorne investigators have relied on the data gathered in one or mostly two facilities 
to perform a costing study. Based on these studies inferences are often made from 
small sample size to regional or national levels. De Graeve et al. calculated 
inpatient costs generated at one University Hospital in Belgium and outpatient costs 
generated at one institutelhospital of 213 seropositive patients without AIDS and 
of 48 AIDS patients, for the ye,ar 1991 (De Graeve et al., 1997). Paul and 
colleagues in 1999 collected information on aIl HIV -positive patients admitted to 
the New York Hospital-Cornell Medical Center in New York City. Data were 
collected from 1 January through JO June 1995, and compared with the same 6-
month time period in 1997(Paul et al., 1999). In 1996 a study was conducted by 
Decock and colleagues to measure the direct costs of HIV care in Belgium. Data oQ. 
service use and costs were obtained through a care-cost diary kept over three 
months. Half out of 82 sequential outpatients returned a completed diary, which 
reduced the sample size considerably. Additional billing data were obtained from 
different sources and by calculating the time spent for certain services (Decock et 
al., 2001). Robins et al. used a retrospective cohort design to measure total medical 
costs for 1 year in a randomly selected sample of 280 patients treated for HIV 
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infection at an urban health care facility. Inpatient and outpatient costs were 
measured from the economic perspective of the health care provider. Hospital costs 
included ward, ancillary, and procedure costs. Ambulatory services included 
medications, primary and specialty care, case management, anci Il ary, and 
behavioral comorbidity treatment costs (Robins et al., 2006). 
1.5.1.2. Indirect versus direct cost estimation 
Indirect costs of HIV as weIl as direct costs should be estimated. Such information 
is very valuable for policy makers in the allocation of resources at country level. 
Mullins and colleagues (2000) estimated annual indirect costs of the HIV epidemic 
in England in 1997-1998 from both a public-sector and societal perspective. 
Estimated population-based indirect costs from the public-sector perspective 
comprised between 58% and 124% of direct treatment costs for triple drug therapy 
in England during 1997. From the societal perspective, estimated population-based 
costs comprised between 45% and 102% of direct treatment costs and cost of care, 
respectively, during 1997. Indirect costs from the public-sector perspective 
included statutory, community, and informaI services; disability costs (including 
disability benefits); and loss of economic productivity. The difference between 
indirect costs estimated from public -sector and societal perspective presented 
separately arise from inclusion of disability costs in the public-sector estimations. 
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The authors believed since disability benefits represent actual costs to the English 
govemment, they could be included in the public-sector analysis. They also 
discussed that disability-related unemployment benefits should be excluded from 
societal perspective estimations considering that disability-related unemployment 
benefits are not truly indirect costs, since they merely redistribute wealth within 
society and therefore are transfer payments. 
In another study by Beck and Mandalia in England in 1999 cost estimates ranged 
from 28% to 34% of total direct costs, assuming a 100% productivity loss and 
adapting a public health sector perspective. Corresponding figures assuming a 50% 
loss of production ranged from 20% to 25%. From a societal perspective, indirect 
cost estimates varied between 22% and 27% of total direct costs, assu~ing a 100% 
loss of production, and between l3 % and 16% of total direct costs when assuming 
a 50% productivity loss (Beck and Mandalia, 2003). 
1.5.1.3. Cines to design or appraise costing stndies 
Beck and colleagues reviewed published studies in English language joumals 
between 1 January 1981 and 30 June 1999 on the costs of HIV service provision 
using a scoring system to screen for the acceptable studies in terms of their quality. 
They devised a set of 10 criteria as indicators of quality and comprehensiveness to 
assess the published cost studies (Table III). 
Table III Review assessment criteria for published cost studies 
Criteria 
1. Minimum of 10 patients in each study group 
2. Bottom-up costing: 
retrospective 
prospective 
3. Minimum period of3 months follow-up 
4. Unit costs: 
charges/priees by year 
unit costs 
5. Patient disease classification: 
disease categories (e.g. Centers for 
Disease Control) 
1 
2 
3 
Case severity indices 
6. Cost components: 
total cost per 
healthcare costs 
drugs 
tests (e.g. CD~count) 
7. Number of treatment centers: 
1 
more than 1 
8. Standardized costs per time unit: 
Score (maximumt 
1(1) 
1 
2 (2) 
1 
1 
2 (2) 
1 
2 
3 
1(4) 
1 
1 
1 
1 (4) 
1 
2 (2) 
no 0 
yes 1 (1) 
9. Analysis: 
point estimate (e.g. mean) 1 
plus measure of variance (e.g. standard 
~~~ 2W 
10. Breakdown of final costs: 
00 0 
yes 1 (1) 
a Each study could score 5 to 20 points. A higher score was 
considered indicative of a combination ofhigher quality or 
cOInpJlet<;mess of methods/results. 
2001 
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Levy and colleagues reviewed published studies reporting the direct medical costs 
of treating HIV-infected people in countries using HAART between January 1996 
and June 2005. They also suggested the following criteria to aid the costing studies 
to be comparable: 
• Range of cost components that are considered in the study. This could 
include inpatient, outpatient, and medication costs. 
• Stratification of cost estimates by prognostic laboratory variables such as 
CD4 cell count, HIV viral load, or by clinical diséase stage. 
• Sources for unit cost measurement used by the investigator. Economic 
theory suggests that unit cost should reflect the opportunity co st of 
resources used in providing a service to HIV -infected patients, although in 
practice, because of difficulties in quantifying this measure, charges or 
average costs are often used as a proxy for opportunity costs. 
• Level at which cost estimates are reported. Reporting cost estimates at the 
lowest disaggregated level would help to the comparability of study results. 
• The timeliness of published estimates as treatment patterns in HIV/AIDS . 
continue to evolve (Levy et al., 2006). 
1.5.1.4. Methods used for cost estimations at nationallevel 
Sorne studies extrapolated the individual cost data to the population data to provide 
information for policy making in the macro level. For instance, Cameron and 
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Tarantola extrapolated the costs to the global level by multiplying annual costs per 
AIDS patient by the estimated number of AIDS cases per country to estimate the 
global inpatient and outpatient costs of AIDS care in 1990 (Cameron and Tarantola, 
1992). Petrou et al estimated totallifetime care costs for an individual with HIV or 
AIDS in England and Wales between 1992 and 1997.Questionnaires and monthly 
diaries were used to collate data on healthcare utilization from 235 patients with 
HIV infection over a 6-month period from 2 clinics in Greater London. Community 
care costs combined with information on hospital data obtained from providers of 
services were used to estimate the annual total direct costs of care and present and 
future total national care costs for England and Wales (Petrou S et al., 1996). 
In a study performed by Beck and Tolley, contemporary cost estimates of treating 
HIV -infected individuals by clinical stage of HIV infection were linked to the 
number of diagnosed HIV -infected individuals using statutory medical services in 
England during 1996 (Beck & ToUey, 1998).In another study, Beck and colleagues 
calculated individual unit cost estimates based on 1997 activity data, and linked it 
to. the number of diagnosed HIV -infected individuals using statutory medical 
services by clinical stage of HIV infection in England during 1997 to obtain 
population-based cost estimates (Beck et al., 1999 ). 
On the other hand, using Medline database for 1990-1998 Rabeneck and colleagues 
reviewed 31 articles focused on adults with a spectrum of HIV disease in which the 
authors developed their' own resource use and cost data. They found wide variations 
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in the estimates and identified three major sources for it: (1) patient sampi es that 
were restricted to subgroups of the national HIV -infected population; (2) utilization 
data that were limited in scope (e.g. inpatient care only); and (3) invalid methods 
for estimating annual or lifetime costs, particularly in dealing with decedents. They 
conc1uded that in order to estimate resource use and costs for HIV care nationwide 
accurately, a nationally representative probability sample of HIV -infected patients 
is required. Even in research that is not intended to provide national estimates, the 
scope of utilization data should be broadened and greater attention to 
methodological issues in the analysis of annual and lifetime costs is needed 
(Rabeneck et al. 1999). 
1.5.1.5. Expenditure studies 
Financial information forms an important component of "strategie information" 
needed to scale up interventions, programs, and services in each country. It falls 
into two broad categories: information on how much is spent on services that can 
come from the government sector or civil society and the actual co st of service 
provision. Expenditure refers to those funds, which are actually being spent at the 
various levels and which for government organizations varies from expenditure at 
centrallevel down to facility or community level (Beek et al., in press). Costs refer 
to the monetary resources required to imp1ement an intervention or provide a 
particular service and is estimated through costing or 'cost-of-illness' studies (Beek 
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et al.,2001). It is estimated by multiplying indices on the use of services by their 
respective unit costs (Beck et al., in press). 
In general, there are fewer expenditure studies in the HIV area compared with HIV-
cost studies. A study in 1998-1999 on national expenditures on HIV in 5 countries, 
describlng the level and flow of health expenditures on HIV, reported that the 
National HIV Accounts constituted a powerful tool to describe the country's 
response to HIV (Izazola-Licea et al., 2002). 
The Regional AIDS Initiative for Latin America and the Caribbean (SIDALAC) 
has served as a supporting body for a number of HIV expenditure studies based on 
the National Health Account (NHA) framework (Izazola-Licea et al., 2000; 
SIDALAC 1999). Studies for Brazil, Guatemala, Mexico and Uruguay have been 
completed as part of this work thus far (Izazola-Licea et al., 2000). The 
methodology adopted by these studies essentially revolves around detining a set of 
activities to be included in the HIV estimates and describe tinancial flows related to 
these activities in the form of three main types of matrices; ultimate tinancial 
sources and tinancial agents, tinancial agents and the providers of care, and 
tinancial agents and the main expenditure categories (prevention, treatment and the 
like). Izazola and colleagues (2000) illustrate this method using Guatemalan data 
(Odumosu et al. 2002). 
Another study undertaken by the Harvard School of Public Health during 1996 and 
1997, relied mainly on mailed questionnaires to collect information on HIV 
expenditures from 64 developing countries and transition economies of Eastern 
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Europe. It provided infonnation on funds provided by governrnent and donor 
agencies, while data on expenditure by households, employers and NGOs, and the 
entire private sector, were not captured by the study. The authors suggested that 
they underestimate national and international HIV spending by nearly one-third 
(Ernberg et al. 1999). 
1.5.2. Trends of costs incurred on HIV service provision 
In the studies do ne before advent of HAART, the majority of HIV costs were for 
inpatient care. Cameron and Tarantola estimated the global inpatient and outpatient 
costs of AIDS care in 1990. They undertook a review of the literature to gauge the 
annual inpatient and outpatient costs per AIDS case. They conducted also a survey 
in 37 countries which provided governrnent expenditures on care of HIV -infected 
persons and those with AIDS. They stated that inpatient care represented 75% and 
90% of total annual care costs in the US and Rwanda, respectively (Cameron and 
Tarantola, 1992).In Jebakumar 's study do ne in England ,the average lifetime cost 
per patient was 18 729 pounds comprising of 45% for inpatient care, Il % for 
outpatient care and 44% for drug therapy. Sixt Y per cent of patients died at home. 
They had examined the inpatient, outpatient and drug therapy costs incurred from 
initial presentation with HIV infection or AIDS to death, where death had occurred 
between 1990 and 1994 (Jebakumar et al., 1995). 
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In the study perfonned by Bozzette et al. in the US, data on service utilization for 
January 1996 to January 1998 were obtained, 43% of overall expenditure was 
estimated to be generated by hospital care, 40% by drugs, 15% for outpatient care 
and associated tests and 2%for emergency department care .They stated that the 
estimated annual direct expenditures for the care of the patients seen during the first 
two months of 1996 were 5,1 billion US$; the expenditures for the estimated 335 
000 HIV-infected adults seen at least as often as every six months were 6.7 billion 
US$ , which was about 20 000 US$ per patient per year (Bozzette et al, 1998). 
Krentz and colleagues categorized and measured the direct costs of medical care 
provided to the entire HIV -positive population receiving care in southem Alberta 
between 1995 and 2001. Since 1995, the direct cost of providing medical care to 
patients with HIV has increased primarily as a result of increased antirelroviral 
drug costs both in absolute and in per patient per month (PPPM) tenns. Mean 
PPPM expenditures increased from 655 US$ in 1995/96, that was, before the use of 
highly active antiretroviral therapy (HAART) , to 1036 US$ in 1997/98 when 
HAART was widely used. During the following 3 years, mean overall PPPM costs 
remained stable. Antiretroviral drugs accounted for 30% (198 US$ PPPM) of the 
total cost in 1995/96 increasing to 69% (775 US$ PPPM) in 2000/01. Inpatient, 
outpatient and home care costs decreased in percentage and cost PPPM between 
1995/96 and 2000/01 from 26% to 10%, 27% to 14% and 8% to 3% respectively 
(Krentz et al., 2003). 
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According to Beck and Mandalia, after the introduction of HAART in 1996, a 60% 
reduction in the number of annual inpatient· days was observed in AIDS patients 
(CDC Group C) in England (Beck and Mandalia, 2003).Increasing HIV prevalence 
especially in non-industrialized countries, has increased overall costs but the advent 
of drug therapies controlling the impact of HIV on health has shifted costs from 
inpatient care towards greater drug, outpatient and social care costs (Beck, Miners, 
and Tolley, 2001 ; Beck and Mandalia, 2003; Levy et al, 2006). 
1.5.3. Problematic issues in cost and expenditure studies 
Even if the appropriate knowledge and skills of the research team are available, 
lack of data affects the quality of the studies in cost and expenditure studies. As 
Levy and colleagues stated, although economic evaluation is an important approach 
for establishing priorities for health interventions, in practice this type of evaluation 
has been of limited value in HIV area because of the paucity of accurate cost data 
(Levy et a1., 2006). 
The lack of data has a long history, as was mentioned in a study by Scitovskey 
et a1. on the cost of care for AIDS as early as in 1988; information on costs has 
been very sparse, especially for children. According to their study, costs were 
expected to become more standardized in the future as c1inical experience with 
AIDS treatment increases and costing methodology becomes more uniform 
(Scitovskey et a1., 1988). 
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In a review of published cost studies by Beck and colleagues in 2001, many of the 
studies were based on small numbers of patients, usually drawn from a single 
centre, and often involving a 'top-down' costing exercise or using prices or charges 
rather than calculated costs. The authors stated the number of high quality studies 
from non-industrialized countries was very limited and another area, which 
similarly requires further attention, is the relative lack of recent data on indirect 
costs in either industrialized or non-industrialized settings (Beck, Miners, and 
Tolley, 2001). 
Even in the last decade, lack of accurate data is remarkable in costing studies. 
In Levy and colleagues' review of literature, of 543 potentially relevant studies, 
only nine provided adequate data to make a meaningful statement about costs. Only 
a small number of studies had been published that provided useful estimates of the 
direct costs (Levy et al, 2006). 
Nowadays lack or inaccessibility of accurate data is more felt in developing 
countries where there is not enough access to basic data, which often are not 
systematically gathered. Beck and Miners point to this problem very c1early as 
follows. "Until recently assessing the use, cost and outcome of HIV service 
provision usually involved collecting information from a single centre through ad 
hoc retrospective studies. If national information was required, inferences would be 
made from the findings of a study performed in a single centre, raising serious 
concems about the representative nature of the information" (Beck et al., 2001). 
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In a recent review on published cost-effectiveness studies, the literature gap in 
sorne areas related to HIV infection has been stated as a matter of great concem, 
especially in deve10ping countries. This review concluded that lack of data might 
significantly affect study results (Harling et al., 2005). In addition, costing studies 
can be extreme1y complex and time consuming to perform. Often the main 
obstacles are scarcity of resources to perform the costing exercise and the lack or 
inaccessibility of data (Beek et al, 2000). 
Lack of data is a considerable problem in expenditure studies as well. 
Most of the expenditure studies do not reflect the exact expenditures incurred on 
HIV activities because of nature of this kind of studies. There might be possibility 
of double counting, inaccurate data and lack of data especially in developing 
countries. Odumosu et al. in 2002 pub li shed the "Plan of Action for a HIV 
Accounts for Nigeria" in which they had reviewed the literature on HIV accounts in 
developing countries. As they stated, in the early 1990s, two studies sought the 
estimation of expenditures on HIV in Asia; one in Thailand during 1991 and 1992 
(Viravaidya et al., 1993), and the other in Sri Lanka on 1993 (Bloom et al., 1997). 
The Thai study had highlighted HIV expenditures by sources of funds; the 
govemment, donors and the private sector. Due to the possibility of double 
counting, the study was not particularly effective in yie1ding an accurate estimation 
of the expenditures on HIV. 
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In addition, they cited many coverage inadequacies in the Sri Lanka study, like 
failure to inc1ude any estimation of household expenditures on prevention and 
treatment. On the other hand, the Sri Lanka study had raised the possibility of 
double counting items listed under sorne of the expenditure categories, by not 
distinguishing between ultimate sources of funding and tinancial 
agentslintermediaries so there was also the possibility of double counting items 
listed under sorne of the expenditure categories (Odumosu et al., 2002). 
Sorne believe that HIV expenditures are becoming more difficult to track even 
among the international institutions. In their opinion, questionnaires are much less 
efficient tools for gathering quality data on domestic resource allocations to HIV, 
because of scarcity of regularly updated information systems that makes it difficult 
for national HIV coordinating bodies to gather expenditure data in a country 
(Opuni et al., 2002). Besides, given the limited data available individual country 
characteristics has made the information provided by UN General Assembly 
Special Session (UNGASS) and Commission on Macroeconomic and Health 
(CMH) estimates, inapplicable to guide resource allocations at the national level 
(Opuni et al., 2002). 
But in the Middle East region, and especially in Iran, studies regarding the cost and 
expenditure of HIV health care provision are even scarcer. Alaka and Jenkins in a 
World Bank publication stated that allocating public funds for an epidemic such as 
HIV involves a decision process quite similar to any other decisions about the use 
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of public funds, but in Middle East and North Africa (MENA) region, the HIV 
activities have been concentrated on medical issues, such as blood supply safety, 
mandatory testing, and increasingly, treatment of AIDS patients while the social 
and economic factors that drive an HIV epidemic have not been adequately 
addressed, either with research or with interventions in this region (Alaka et al., 
2005). 
ln the case of Iran, except for the UNGASS report in 2006, literature search 
identified no published studies on the cost and expenditure of HIV health care 
provision. 
The Iranian published studies fell into 4 groups inc1uding prevalence and potential 
risk factors of HIV infection, HIV prevention, attitude and knowledge towards 
HIV, and c1inical aspects ofHIV. 
ln the UNGASS 2006 report, which is based upon a project implemented from 
November to December 2005, the estimate of national funds disbursed by the 
government throughout the country in 2004 was calculated by the authors using 
data from the following sources as described in box 3. 
Box 3 Measurement instruments in UNGASS report, Iran 2006 
1. Review of the 2004-2005 fiscal budget bills 
2. Review of Memorandum ofUnderstandings among HIV/AIDS control 
programs in 2004-2005 
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3. Enquiries about expenditure from ministry officiaIs and other organizations 
with budgetary allocations for HIV control activities. 
4. Enquiries about HIV prevention and control expenditures from 40 medical 
universities 
Total funds constituted of 14 items and the authors recommended implementing the 
National AIDS Accounts to provide more accurate estimations in this regard 
(Country Report on UNGASS Declaration ofCommitment, 2006). 
1.6. HIV situation in Iran 
The first case of HIV in Iran was diagnosed in 1987(Iran Ministry of Health, 2006). 
The probable transmission mode was contaminated blood transfusion. In 1989, the 
first HIV positive woman was identified, and the first AIDS-related female death 
was recorded in 1990 (Epidemiological Fact Sheets, 2004). From then the epidemic 
shifted from a "low" to the "concentrated" level. 
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Based on the reported data, the HIV epidemic in the Islamic Republic of Iran 
appears to be accelerating. The first increase occurred in 1995, when the number of 
HIV cases reached 815 new infections (Epidemiological Fact Sheets, 2004). 
According to reports by the National AIDS pro gram , the number of 1159 people 
newly diagnosed with HIV or AIDS in 2001 showed a three-fold increase in 
comparison to both 2000 and 1999 (Epidemiological Fact Sheets, 2004); 
Table IV shows estimated number of People Living with HIV (PLHIV) according 
to the UN in 2003(Epidemiological Fact Sheets, 2004). In this report, adults are 
defined as women and men aged 15 to 49. This age range co vers people in their 
most sexually active years. While the risk of HIV infection obviously continues 
beyond the age of 50, the vast majority of those who engage in substantial risk 
behaviors are likely to be infected by this age. The 15 to 49 range was used as the 
denominator in calculating adult HIV pre~alence. 
Table IV Estimated number of people living with HIV (PLHIV) in Iran. 
Estimated number of adults and children living with HIVIAIOS. end of 2003 
These estimates include ail people with HIV infection, whether or not they have developed symptoms of AIDS, 
alive at the end of 2003: 
Adults and children 
Low estimate 
High estimate 
Adults (15-49) 
Lowestimate 
High estimate 
Children (0-15) 
Low estimate 
High estimate 
Women (15-49) 
Low estimate 
High estimate 
31,000 
10,000 
61,000 
31,000 
10,000 
60,000 
3,800 
1,200 
7,400 
Estimated number of deaths due to AlOS 
Mult rate (%) 
Low estimate 
High estimate 
Estimated number of adults and children who died of AIDS during 2003: 
Adults and Children 
Low estimate 
High estimate 
800 
300 
1,600 
0.1 
0.0 
0.2 
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Based on census data, from the first reported HIV positive person till 2005, 10265 
asymptomatic HIV infected has been reported from aIl provinces to CDC III 
Tehran. Out ofthem 390 had AIDS and 1077 died (Pourmalek et al., 2005). 
By late September 2005, the estimate of people living with HIV (adults and 
children) in Iran was 66 000 with the range of 36 000 - 160000. Estimates for 15 
years and above adults were the same. Prevalence rate for 15 -49 years adults was 
estimated as 0,2% (0,1 % - 0,4%). Estimates of 15 years or older women living 
with HIV was Il 000 (5 200 - 28 000) (UNAIDS, 2006) .. 
Over the 2000-2004 period the proportion of women among PLHIV rose from 
5,0% to 5,8% (Iran Ministry of Health , 2006) 
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Based on the latest official statistics published by September 2006, the t~tal 
number of people living with HIV or AIDS was reported as 13 702, of whom 96% 
were male. The 25-34 year-old age range comprised 41 percent of cases, foHowed 
by 31 % among the 35-44 year-olds (Iran Ministry of Health, 2006). 
AIDS deaths in adults and children were estimated as 1 600 (920 - 2700) in 2005 
(UNAIDS, 2006).By September 2006, 1709 of those infected with the virus had 
died (Iran Ministry of Health 2006). 
Regarding route of HIV transmission, injecting drug use currently predominantly 
drives the epidemic in Iran. In 2001, 64% of aH AIDS cases were injecting drug 
users (Epidemiological Fact Sheets, 2004). In 2004, injecting drug use was still the 
main source of transmission ofHIV in Iran (63%), while sexual contact was said to 
be the second most important route of transmission at 7,3 %; 26,1% of the cases, 
however, were grouped as unspecified route of transmission (Gheiratmand et al., 
2005). 
According to CDC report, mode of transmission in 65 % of the reported cases 
involved sharing needles and syringes in 2006. The figures for sexual contact, 
infusion of contaminated blood products and mother-to-child transmission were 
7%, 2%, and 1 %, respectively. In 26% of the cases, mode of transmission was 
unknown (Iran Ministry of Health, 2006) 
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The statistics regarding HIV prevalence in IUDs in Iran are disputed. Arnong IDUs 
who had been referred to the counseling centers, 6% in 1996, 2% in 1997. 9% in 
2002 and 29% in 2002 were HIV positive (Epidemiological Fact Sheets, 2004). 
In 2004, there were an estimated 2,0 to 2,5 million drug addicts in Iran .If one adds 
occasional drug users this figure increases . 10-15% of them are IDUs, that is 
200000 to 300 000 IDUs. Ofthese, 20-25% are HIV positive, which gives at least 
40000 to 60 000 HIV positive IDUs (Iran Drug Control Headquarters' news, June 
2005). According to the Iran Ministry of Health, 70 000 people in Iran were living 
with HIV and 137 000 were injection drug users in 2005. The Director of CDC in 
Iran Ministry of Health stated that about 64% of HIV cases occurred through 
injection drug use, and the rate of drug use is increasing by about 8% per annum 
(Gheiratmand et al., 2005; Daily HIV report, kaisernetwork, 2006). 
CHAPTER2 
Objectives 
& 
Stndy Methods 
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2.1. Objectives 
2.1.1. General objective 
To detennine HIV expenditures on. prevention, treatment, care, and support 
services in Iran in 2004. 
2.1.2. Specifie objectives 
1. To describe demographic, transmission characteristics and first CD4 counts 
by disease stage and death in the HIV positive inpatients hospitalized at 
Imam Khomeini hospital infectious disease ward. 
2. To detennine inpatient rate per year, mean inpatient days per patient, mean 
hospitalization time per patient at Imam Khomeini hospital infectious 
disease ward. 
3. To estimate the inpatient cost per individual per day in Imam Khomeini 
hospital infectious disease ward. 
4. To describe demographic, and transmission characteristics, first CD4 
counts, and ART of the outpatient clients seen in the Imam Khomeini VCT 
center by disease stage and death. 
5. To detennine the number of outpatient visits for HIV positive clients, 
number of people (HIV positive or HIV negative) referred to Imam 
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Khomeini and other selected VCT centers. 
6. To estimate the outpatient cost per individual per year and outpatient cost 
per visit in Imam Khomeini VCT center. 
7. To estimate the average outpatient co st per visit in selective VCTs in the 
country. 
8. To determine the HIV expenditures of the other areas inc1uding: ART, 
blood testing and screening, and public education. 
9. To estimate overall HIV expenditures on prevention, treatment, care, and 
support services in Iran, 2004. 
2.2. Methods 
This study aimed to estimate t~tal expenditure on HIV -related health services at the 
nationallevel in Iran during 2004. Given the country programs for disease control 
as implemented by the CDC in Iran, the total country expenditure areas on HIV 
comprises seven main programs. The programs are (Iran Ministry of Health, CDC, 
2003): 
1) Program for inpatient care (hospitalization); 
2) Program for outpatient care, consultation, and education of the HIV 
positives and their families; 
3) Program for provision of antiretroviral drugs (ART); 
4) Program for blood testing and screening; 
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5) Program for public infonnation and school students' education; 
6) Pro gram for hann reduction activities; 
7) Program for HIV control at anned forces' health care centers. 
Expenditures had to be estimated based on bottom-up estimates for outpatient and 
inpatient services. Because of paucity of infonnation, especially at health facility 
leve1, expenditures could not be tracked right down to these levels. It was for this 
reason that a second, less preferable, method had to be employed at health facility 
level. This method infers HIV expenditure in health facilities by estimating the use 
of services, which combined with unit costs, pro duce an estimate of costs at health 
facili~y level. Similar situations have been found to exist in a variety of countries 
and the UNAIDS-Ied National AIDS Spending Assessments (NA SAs) have had to 
employ similar methods as had to be resort to in this study (UNAIDS. National 
AIDS Spending Assessment (NASA), 2007). 
Other expenditure items could be estimated by using a top-down approach but no 
documentation of expenditures at the peripheral level could be identified , due to 
the centralized mode of service delivery. 
This was observed in the following areas of expenditure: 
1) Antiretroviral Therapy medicines distributed by Center for Disease Control 
of Ministry of Health in Tehran; 
2) Blood testing and screening for HIVby Blood Transfusion Organization; 
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3) HIV prevention health education programs by Ministry of Education, and 
public health education for HIV prevention by Islamic Republic of Iran 
Broadcasting agency. 
4) Harm reduction activities inc1uding syringe and needle distribution, 
methadone maintenance treatment (MMT), basic health care, counseling 
and education services. These are mostly intervened by healthcare staff, 
outreach teams, peers and other volunteers in Drop-in Centers (DICs), 
VCTs, prisons, Welfare Organization's health care centers, Iranian Red 
Cres cent Society's health care centers, and pharmacies. 
5) HIV control and prevention in the armed forces' health care centers. 
The inpatient and outpatient co st estimations were used as a proxy for expenditure 
estimation at the national level. On this basis, an overall estimate of HIV related 
preventive, treatment, care and support expenditures in Iran during 2004 was 
obtained. 
2.2.1. Data collection 
A 'record abstraction form' was developed for abstracting our intended variables 
from outpatient records in Imam Khomeini hospital. A 'case note abstraction form' 
was also developed for abstracting inpatient case notes in Imam Khomeini 
hospital's infectious disease ward (appendix 2, page 135). The two data abstraction 
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fonns used for inpatienis and outpatients had a common part for socio demographic 
infonnation, and each had a specific part for outpatient or inpatient data. We 
validated the "record abstraction fonn" in tenns of within and between observer 
reliability. The details about validation are described in appendix 1 page 129. 
2.2.2. Sources of data 
2.2.2.1. Sources of data for inpatient analysis 
Inpatient and financial data were gathered from Imam Khomeini hospital infectious 
disease ward. The oldest data regarding HIV positive inpatients available in this 
ward was related to a few patients hospitalized in 2000. The data we gathered 
inc1uded aIl available inpatient data related to those who were HIV positive or had 
AIDS and had been referred from private or public c1inics and admitted in this 
ward in 2004. 
In Iran, HIV patients are mostly referred to university hospitals when 
hospitalization is needed because of their specialist services. Since aIl the 
university's hospitals use the same tariffs, and the same HIV treatment protocols, 
the data from Imam Khomeini hospital was assumed to be representative of that of 
other universities' hospitals. 
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As the National Strategic Plan on Confronting HIV of Iran's CDC had not been 
implemented completely in 2004, the data regarding disease stage were extremely 
incomplete and almost all inpatients were recorded as asymptomatic HIV and 
records to prove clinical stage were not available. According to Iran CDC records 
the HIV positive people in the mentioned year were mostly IDUs. Unfortunately, 
many of their family members often do. not take responsibility of these people 
living with HIV, which include that they do not accept any financial 
responsibilities(Professor Minoo Mohraz, Tehran University of Medical Sciences, 
personal communication, May 2004). Thus, we expected large amount of lost -to -
follow up for inpatients in this year. Another reason might be that they would be 
referred back to the private clinics to be cared for. In 2004, there was only one HIV 
referral private clinic located in Tehran and all clinicians working there were 
academic members of Tehran University, who referred their patients to Imam 
Khomeini hospital infectious disease ward to be hospitalized. Thus, we went to that 
private clinic and compared the name and characteristics of the recorded inpatients 
with the inpatient records and found out the number of inpatients who had AIDS in 
the study data gathering time (2004). 
Mean inpatient days per patient and mean hospitalization times were calculated 
from data gathered from Imam Khomeini infectious disease ward. But there were 
no data regardinginpatient rate available at this ward. It means, there were no data 
regarding the number of HIV positive seen in the hospital for IP+OP services to be 
able to calculate the inpatient rate at Imam Khomeini hospital infectious disease 
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ward. In order to deal with this problem and use it in the inpatient co st estimation, 
we relied on the data from Imam Khomeini VCT center. In this center the staff send 
the clients to the hospital to be hospitalized if needed. As the Imam Khomeini VCT 
is located beside Imam Khomeini hospital infectious disease ward, clients were 
likely to be referred to the same ward. Thus, in the denominator of the "inpatient 
rate" fraction, we put the number of outpatients who had history of hospitalization 
in one year in their records. 
Demographic and transmission characteristics, tirst CD4 count, information on anti 
retroviral treatment (ART), and death data by disease stage were also collected 
from case reports in Imam Khomeini infectious disease ward. 
Demographic data collected included sex, age (in year) , and marital status. 
Transmission characteristics included history ofIDU, history ofunsafe sex, detined 
as penetrating sex without using a condom, history of blood and blood transfusion 
during their life, history of mother to child transmission (MT CT) or being bom 
from an HIV infected mother, and history of imprisonment in their life. Although 
being in prison in itself is not a risk factor for HIV infection, it increases 
vulnerabilityto and risk of infection in prisoners through injecting drugs with non-
sterile needles or having unprotected sexual intercourse. The current research 
includes both children and adults seen. There were no data available regarding 
ART prescribed on Imam Khomeini infectious disease ward at the time we 
gathered data. 
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Disease stage was defined as: Non AIDS, and AIDS. 
• Non AIDS stage was defined as: When patient was infected with HIV but 
remained asymptomatic (asymptomatic HIV stage) and also if the patient 
had developed symptomatic disease, which was not an AIDS-defining 
condition (symptomatic non AIDS stage) (CDC classification stages A&B) 
(Revised Classification System, CDC, 1993). Infection with HIV was 
confirmed by an ELISA positive test followed by a positive Western Blot 
test. 
• AIDS stage was defined using the 1993 CDC AIDS defining criteria, CD4 
count less than 200 or clinical signs and symptoms of HIV related 
opportunistic infections (e.g. brain toxoplasmosis, brain lymphoma, etc.; 
CDC classification stage C) (Revised Classification System, CDC, 1993). 
Regarding death, it was hoped that cause of death were recorded in the medical 
records. Lost-to-follow-up data was also very important but because of po or case-
records, we were unable to gather complete data on the date, cause, and place of 
study subject's death, nor did we find data on loss to follow up rate. The only 
available data on death was whether he or she had died or not. 
2.2.2.2. Sources of data for outpatient analysis 
Outpatient services are provided by outpatient HIV healthcare centers. They 
include the Triangular Clinics, that provide voluntary counseling and testing along 
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with other services, and are caUed "VCTs". Thus VCTs, in addition to counseling 
and testing services, provide outpatient care and treatment. The HIV healthcare 
centers are established and supervised by Medical Universities, which are executive 
branches of the Ministry of Health at provinciallevel, and each Medical University 
supervises a number of VCTs in close collaboration with the HIV/AIDS Office in 
MOH. 
To estimate outpatient costs at clinic level, we focused on Imam Khomeini 
Triangular Clinic and Voluntary Counseling and Testing (V CT) center. This center 
is located in the Imam Khomeini Hospital beside the Imam Khomeini hospital 
infectious disease ward and is supervised by Tehran University of Medical 
Sciences. It was established in 2004. AU data from May 2004 till July 2005 in this 
VCT were transferred onto the record abstraction forms. 
We also gathered outpatient and financial data from 5 selected VCTs in the country 
other than Imam Khomeini VCT .This provided us with a gre~ter range of 
outpatient. activities and co st data based on activity data, including number of 
outpatient visits for HIV positive and HIV negative clients at these VCTs. Financial 
data were related to year 2004. Then we considered outpatient co st per visit as cost 
unit to estimate total outpatient expenditure for both preventive and therapeutic 
HIV services in the country in 2004. 
Clinics affiliated with the institutions such as Welfare Organization (WO), Prisons 
Organization (PO) and Iranian Red Crescent Society (lRSC) also provide HIV 
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prevention, care and support services and are in close collaboration with CDC. We 
also considered the above mentioned organizations' expenditures at country level 
expenditure estimation (Country Report on UNGASS Declaration, 2006). 
Demographic and transmission characteristics, first CD4 count, information on anti 
retroviral treatment (ART), and death data by disease stage were collected from 
client records. Definition of demographic and transmission characteristics and also 
disease stage were the same as described for inpatients. 
2.2.3. Data analysis 
Analyses were performed separately for inpatients and outpatients. 
Demographic and HIV transmission characteristics, first CD4 count (cells/mm3), 
and whether they were on antiretroviral therapy were recorded for HIV positive 
patients by disease stage, and among those who had died of the disease. 
Regarding demographic characteristics, sex, age, and marital status were described. 
Age was categorized as 0-24, 25-44, and 45+ years. Marital status was categorized 
as: married, unmarried, divorced, separated, and widowed (only in outpatients). 
The three last ones are collapsed into one group (group 3). 
History of IDU, unsafe sex, blood and blood born transfusion, mother to child 
• 
transmission (MTCT), and imprisonment are described as transmission 
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characteristics of the HIV positive people by their disease stage and death. Data on 
ART was only available at Imam Khomeini VeTo 
We used SPSS (Statistical Package for Social Sciences) version 11.5 and Exce1 
software for data analysis. Estimated expenditure and costs are expressed in Rials 
of 2004 prices. In 2004, the conversion factor between US$ and Iranian Rial was 
8459,16 while the conversion factor between International $ and Iranian Rial was 
2742,133 (World Development Indicators, 2006). 
Finally, figures were rounded offto their nearest number if necessary. 
2.2.4. Inpatients 
2.2.4.1. Inpatient services cost 
We collected data from HIV positive patients' case notes and financial records in 
the hospital retrospectively, for those hospitalized at Imam Khomeini hospital 
infectious disease ward in 2004. This was prone to information bias. 
Representativeness of data might also be affected. 
We used 2004 patient records for inpatient cost estimations. The data inc1uded 
hospital's overhead costs but exc1uded start up (capital) costs of new equipment or 
additional services. We ca1culated the inpatient (IP) cost per individual per day of 
hospitalization and also IP co st per patient in 2004 at Imam Khomeini Hospital 
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infectious disease ward. 
Mean inpatient days per patient, inpatient rate per year and mean hospitalization 
times were calculated using the foHowing formula: 
Mean inpatient days for each HIV positive inpatient = (total inpatient days of the 
HIV positive inpatients in Imam Khomeini hospital in one yeart) / (number of the HIV 
positive inpatients hospitalized at the Imam Khomeini hospital in the same year). 
t Total inpatient days of the HIV positive inpatients in Imam Khomeini hospital in 
one year inc1udes aH days for one or more hospitalization of the inpatients in that 
year. 
Inpatient rate = (number ofHIV positive inpatients admissions in one year in Imam 
Khomeini hospital) / (number of HIV positive people seen in the hospital for 
IP+OP services in the same year) xl 00 
Mean hospitalization time = (Total episodes of hospitalization for a group of HIV 
positive inpatients in a time period in Imam Khomeini hospital) / (number of 
hospitalized inpatients in the same group at the same time period in Imam 
Khomeini hospital) 
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In the next step, we used these data to infer inpatient costs in the country and used 
it as a proxy for total HIV IP expenditure estimation in Iran. 
2.2.4.2. Inpatient services expenditures 
We used inpatient cost data described above and gathered from the HIV positive 
inpatients hospitalized at Imam Khomeini Hospital, as the national university 
referral hospital for infectious disease, inc1uding HIV and AIDS as a proxy for 
inpatient expenditure estimation in the whole country. The following fonnula was 
used: 
Inpatient costs at country level = (inpatient cost per day x average inpatient days 
for each HIV positive inpatient) x (number of HIV positive patients hospitalized in 
one year in the country). 
Number of HIV positive patients hospitalized in one year at the national level = 
(inpatient ratet x HIV positive population, alive in the whole year) + (HIV positive 
population deceased in the same year:n 
t Inpatient rate is calculated from fonnula 2. +The HIV positive deceased in a year, 
receive hospitalization services at least at the last months/days of their lives as put 
in the assumptions. 
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In hospitalization co st items we excluded non-recurrent costs such as costs for 
starting up new sections/services or preparing new equipments, luxury costs for 
private hospitalization, logistics and research costs financed by CDC or 
universities' head offices. Such costs are defined as parts of non-individually or 
collective services, which are not directly consumed by individuals. This does not 
cause underestimation because according to the System of National Account (SNA) 
manual the corresponding costs for individual services excludes the co st items for 
fixed capital (building and equipment) and collective costs such as logistics and 
research (Organization for Economic Co-operation and Development, 1993). 
Also, in this study the distinctions between individual and collective serVices and 
between consumption expenditure and capitallormation expenditure correspond to 
the relevant definitions in the SNA 1993 explained above. Hence, logistics and 
research expenditures, which are financed by CDC or universities head offices, are 
not considered in the expenses and co st items, since they are parts of collective 
costs. Also, capital or equipIilent and other start up costs for new hospital sections 
are not included in inpatient co st estimations, since they are not parts of yearly 
current costs. 
2.2.4.3. Assumptions for inpatient expenditure estimation at 
nationallevel 
The following assumptions were made to estimate the inpatient costs for people 
living with HIV in Iran: 
67 
1. Inpatient services III Imam Khomeini hospital infectious ward are. 
assumed to be typical of the services for public HIV positive 
hospitalization. A verages per inpatient cost in public tertiary hospitals in 
Iran were assumed to be equal to the estimates obtained from Imam 
Khomeini hospital. 
2. Similarly, the Imam Khomeini hospital infectious ward was assumed to 
be representative in terms of admissions of HIV positive patients and 
associated inpatient rates for HIV positives in Iran. 
3. Overhead costs for inpatient services which are directly provided for 
inpatients (e.g. costs oflaundry, electrical costs, c1eaning services, etc), 
are inc1uded in the inpatient cost estimations as parts of expenses. 
4. The HIV positive deceased in a year, receive hospitalization services at 
least in the last days or months oftheir lives. 
2.2.5. Outpatients 
2.2.5.1. Outpatient services costs 
Using data for total number of visits at Imam Khomeini VCT center in 2004, we 
estimated the outpatient cost per visit. The co st items in this VCT are as shown in 
box 4. 
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Box 4 Cost items at Imam Khomeini Triangular clinic and VCT center 
1- Personnel salaries. 
2- Maintenance, rent, transport, and utilities. 
3- Medical supplies (e.g. condom, syringe, etc.), consumables. 
4- Non medical/administrative supplies and durable goods (e.g. computer, 
printer, etc.) 
5- Non-specific labonÎtory tests e.g.CBC, and vaccination, etc. 
6- Medicines other than HN specific Antiretroviral Therapy (including 
antibiotics, methadone, etc.). ART expenditure is included in top-down 
expenditure by Center for Disease Control explained in chapter 3. 
7 - Education materials and activities. 
As all above cost items are paid for by the government, we collected data from 
financial department of Imam Khomeini VCT and considered it as the total costs 
for activities done there in visiting the clients. In this study, "visit" includes all 
preventive and therapeutic services delivered to the people at VCTs or Triangular 
Clinics, including laboratory tests, counseling, condom delivery and family 
planning activities, outpatient care, provision of Antiretroviral Therapy medicines, 
methadone therapy, and harm reduction activities ,etc. 
The next step was to estimate the average number of annual visits for each HIV 
positive and HIV negative client based on the Imam Khomeini VCT data .Based on 
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this the cost for each outpatient visit in Imam Khomeini VCT center in 2004 was 
estimated as was the outpatient cost per individual per year. 
2.2.5.2. Outpatient services expenditures 
We also gathered outpatient cost data from 5 selected VCTs in the country other 
than Imam Khomeini VCT in order to have more representative estimates on 
costing and activity data for HIV outpatient service provision in Iran. 
The number of HIV positive outpatient visits during 2004, number of outpatient 
visits from both HIV positive or HIV negative people referred to the 5 other VCT 
centers during 2004 were also collected. Expenditure on both HIV positive and 
HIV negative use of outpatient services were costed. However, HIV positive people 
will use services more frequently than HIV negative people and in order to estimate 
the mean number of OP visits for HIV positive people, this had to be estimated 
separately from the HIV negative people, before an overall estimate ofuse and cost 
of OP services by HIV positive and HIV negative people could be estimated . 
The five centers mentioned were located in Kurdistan, supervised by Kurdestan 
Medical University; Fars, supervised by Shiraz Medical University; Lorestan, 
supervised by Lorestan Medical University; West of Tehran ,supervised by Iran 
Medical University in Tehran; and Kermanshah, supervised by Kermanshah 
Medical University. Relevant financial data were also obtained from these centers. 
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According to CDC, the VCTs identified, which are affiliated with the 6 selected 
Medical Universities, coyer most outpatient RIV services in the country. These 
financial data were also used as proxy for expenditure estimation at country level. 
The cost items in each VCT were the same (box 4, page 68) .Average outpatient 
cost per visit in each VCT was obtained by dividing total cost of the 6 chosen 
VCTs by the number of visits done in these 6 VCTs. Then, the average for the 
VCTs related to the 6 universities, or the outpatient cost per visit across aIl VCTs, 
was estimated. We also estimated the range and average visits per client using 
staffs' experience and opinion and sorne available data in the 6 VCTs. 
We performed sorne sensitivity analyses, considering different scenarios regarding 
probable annual number ofvisits and financial sources that is described in follow. 
Using CDC statistics for the number of reported RIV positive cases in 2004, we 
estimated the total number of outpatient visits in the country. Multiplying the latter 
figure by the outpatient cost per visit, and then adding them to the expenditures in 
the 3 other RIV outpatient service delivery clinics affiliated with Welfare 
Organization, Prisons Organization, and Iran Red Crescent Society total outpatient 
expenditures in Iran in 2004 was estimated. 
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2.2.6. Other areas of services expenditures 
HIV-related expenditure of the following other organizations ln 2004 were 
obtained, whose expenditure items were available at the nationallevel: 
1. Antiretroviral Therapy medicines distributed by CDC to provinces and 
Universities of Medical Sciences. In this regard, we inc1uded total ART 
expenditures in the country in our expenditure estimation. We assumed 
that 100% drugs are distributed and consumed by eligible HIV or AIDS 
patients. Thus, using a top down approach for ART expenditures is 
reasonable. As CDC pays for ART and ensures distribution of the drugs 
at facility level, it is assumed that double counting is avoided in this 
regard. 
2. Blood screening and HIV tests performed by Iranian Blood Transfusion 
Organization. 
3. HIV prevention health education for students by Ministry of Education 
and public health education for HIV prevention by Islamic Republic of 
Iran Broadcasting agency. 
4. Harm reduction activities inc1uded those performed by outreach teams, 
peers and other volunteers in Drop-in Centers (DICs), and pharmacies. 
The harm reduction interventions at VCTs, prisons, Welfare 
Organization health care centers, and Iranian Red Crescent Society 
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health care centers are inc1uded in the outpatient expenditures described 
above. 
5. HIV control and prevention in the c1inics affiliated with the armed 
forces. 
2.2.7. Total national HIV expenditure 
The overall national HN expenditure was obtained by adding the 7 areas of 
expenditure, as well as provides a breakdown by primary prevention or secondary 
prevention programs. Primary prevention programs inc1uded blood testing and 
screemng programs provided byBlood Transmission Organization, public 
education programs provided by Ministry of Education. Secondary prevention 
programs inc1uded inpatient services and provision of anti retroviral treatment. We 
categorized outpatient services, harm reduction activities and services provided in 
the armed forces' c1inics as a separate category as these inc1uded both primary 
prevention programs such as consultation and harm reduction but also secondary 
prevention programs such as ART, methadone or antibiotic therapy. 
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2.2.8. Sensitivity analysis 
Using the assumptions for outpatient costs, there may be sorne differences iil total 
HIV expenditure based on variations in local referral patterns the implementation 
of the national HIV program. To provide more rigorous estimates, we performed 
sensitivity analyses with two upper and lower limits around the point estimates of 
expenditures. The variation (uncertainty) factors wereas follows: 
1. Yearly average of outpatient visits for HIV positive people at VCTs: point 
estimate: 7 visits; lower limit: 4 visits (one visit per season); upper limit: 12 
visits (one visit per month). The range is obtained from 6 above mentioned 
VCTs. This provides 3 scenarios for outpatient costs. 
2. Maximum annual costs in each VCT equals to 1500 million Rials. This 
amount is the average of the two busiest VCTs (Lorestan and Kermanshah) 
(table VIII page 89). This gives rise to two other scenarios for each of the 
scenarios mentioned above. 
Therefore, there would be 6 following scenarios for the total outpatient costs: 
Sçenario 1: Total costs at each VCT are the same as is reported by the 
university financial department; yearly average of outpatient visits for HIV 
positive people at each VCT is 4. 
Scenario 2: Total costs at each VCT are the same as lS reported by the 
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university financial department; yearly average of outpatient visits for HIV 
positive people at each VCT is 7. 
Scenario 3: Total costs for VCT are the same as is reported by the university 
financial department; yearly average of outpatient visits for HIV positive people 
at each VCT is 12. 
Scenario 4: Total costs at the VCT affiliated with one university are equal to 
1500 million Rials (the highest amount it could be); yearly average of 
outpatient visits for HIV positive people at each VCT is 4 (1 visit/season). 
Scenario 5: Total costs at the VCT affiliated with one university are equal to 
1500 million Rials (the highest amount it could be); yearly average of 
outpatient visits for HIV positive people at each VCT is 7. 
Scenario 6: Total costs at the VCT affiliated with one university are equal to 
1500 million Rials (the highest amount it could be); yearly average of 
outpatient visits for HIV positive people at each VCT is 12 (1 visit/month). 
Of aIl these scenarios, scenarios 1 and 6 provide lower and upper limits around the 
point estimate (scenario 2). 
CHAPTER3 
Results 
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3.1. Inpatients 
3.1.1. Demographie eharaeteristies 
16 inpatient episodes were recorded in the case notes of 13 people who could be 
identified as being HIV positive in 2004. 9 (69%) had AIDS and 4 (31 %) non 
AIDS. Of the 13,6 (46 %) had died: 3 non-AIDS and 3 AIDS inpatients died. An 
of the inpatients were men. 
The most frequent age group among inpatients was greater than 45 years. 53.8 % of 
inpatients were in this age group. Of them 66.7 %(4/6) had died which was the 
highest number of death among agegroups. In the non-AIDS group who were 
greater than 45 years, 3 out of 4 died and in the inpatients who had AIDS and were 
greater than 45 years 1 out of 4 died. In the 25-44 year age group, 2 out of 6 AIDS 
patients died. 
For 46 % (6 /13) of inpatients there was no data on their marital status. Among 
dead inpatients 2 out of 4 died among those who were not married and 2 out of 4 
married individuals died. Data regarding demographic characteristics of inpatients 
are summarized in table 1. 
Table 1 Demographic characteristics of inpatients by disease stage; Imam 
Khomeini Hospital infectious disease ward, 2004. 
Disease Stage Non 
N(%) 
Age group (year) 
3.1.2. Transmission characteristics 
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5 out of 13 inpatients (39%) had a history of IDU. Out ofthese 60% had AIDS and 
the rest, 40 %, non AIDS. 3 out of 6 inpatients who died had a history of IDU and 3 
out of the 5 IDUs died. For those with AIDS, one IDU died. Regarding history of 
unsafe sex, none of inpatients have had such a history. None of the 13 inpatients 
had the history of blood and blood products transfusion. 3 out of 13 (23%) had a 
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history of imprisonment before being hospitalized: needle sharing is common ln 
IDU prisoners. 2 had AIDS and one non AIDS. 
Table II Transmission characteristics of inpatients by disease stage; Imam 
Khomeini Hospital infectious disease ward, 004. 
Disease Stage Non AlOS AlOS Total 
N (%) N (%) N (%) 
History of Injecting Drug Use (IDU) 
History ofUnsafe sex 
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3.1.3. First CD4 count 
Only 3 out of 13 inpatients had their tirst CD4 count after admission recorded. An 
had AIDS. There were no data regarding tirst CD4 count in those who died. Mean 
of the tirst CD4 count was 26.67 cens/mm3 with median of 30 cens/mm3. 25% of 
the inpatients in the AIDS stage had a tirst CD4 count of less than 20 cens/mm3 
and 75% less than 30 cens/mm3. 
Table III Description of tir st CD4 counts /mm3 of inpatients in AIDS stage; Imam 
Khomeini Hospital infectious disease ward, 2004. 
3.1.4. Inpatient use of services 
In 2004, there were 13 HIV positive inpatients who generated 16 hospitalizations. 
The mean nu~ber of hospitalization per patient per year was 1,23. Total inpatient 
days were 323 for 13 inpatients. Thus, mean inpatient days per patient per year was 
24,8 days and per admission 20,2 days. 
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Between May 2004 and July 2005, of the 339 HIV positive people seen at Imam 
Khomeini VCT center, 10 people were hospitalized in Imam Khomeini hospital 
infectious disease ward. Thus, for 15 months the inpatient rate was 2,95% (10/339), 
and hence, after adjusting to 12 months the rate reduced to 2,35%. 
3.1.5. Inpatient expenditures 
3.1.5.1. Inpatient services costs at hospitallevel 
The 13 inpatients generated a cost of 54 154 492 Rials in 2004.The inpatient cost 
for each admission amounted to 3 384656 Rials and hospitalization cost per person 
was 4 165 730 Rials .Total inpatient days for the above study subject was 323 days 
and cost per inpatient day amounted to 167 661 Rials or 19, 8 US$ and 61,1 Int $. 
3.2. Outpatients 
3.2.1. Demographie eharaeteristies 
698 people were referred to Imam Hospital VCT center from May 2004 until July 
2005, of whom 339 (49%) were HIV positive patients who came for outpatient 
treatment and care: 119 out of 339 outpatients (35%) had AIDS. Of aIl outpatients, 
18 (5 %) died during the study period from May 2004 until July 2005: 8 were non 
AIDS patients and 10 had AIDS. 89% of outpatients were men and aIl outpatients 
who had died were also men. 246 out of 339 outpatients were in the 25-44 year age 
group. Of these 4% had died. 10% of non AIDS outpatients had died compared 
with 1 % of AIDS patients. The demographic characteristics of outpatients are 
shown in table IV. 
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Table IV Demographic characteristics of outpatients by disease stage and death 
status; Imam Khomeini VCT center, 2004. 
AIDS. Total 
N (%) N (%) 
Total 
* Divorced/ Separated/ Widowed 
on 
AIDS 
N (%) 
AIDS 
N (%) 
Total 
N (%) 
@: Disease stage of the 6 cases ofdeath,3 in the age group of25-44 and 3 in the missing age group, were not 
recorded 
® Disease stage of the 5 cases of death (in males) were not recorded. 
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3.2.2. Transmission characteristics 
212 out of 339 outpatients (63%) had a history of IDU (table V) , 28% of whom 
had AIDS. Only 8 out of 18 outpatients who died had a history of IDU. For IDUs 
with'AIDS, death had occurred in 6 out of 59. In non AIDS IDU outpatients, death 
had occurred in 2 out of 153. 
26% of outpatients had a history ofunsafe sex, ofwhom 32 (37%) had AIDS. 
3 out of 87 of the outpatients with the history of unsafe sex had died, aIl of whom 
had AIDS. 31 out of 339 outpatients (9%) had a history of blood and blood 
products transfusion, of whom 23 had AIDS. One of 31 HIV patients with the 
history ofblood and blood products transfusion had died. 
198 out of 339 (58%) had a history of imprisonment, of whom 30% had AIDS. 8 
out of 198 had died. 
Table V Transmission characteristics of outpatients by disease stage and death 
status; Imam Khomeini VCT center, 2004 
Disease State Non AlOS 
N (%) 
History of Injecting Drug Use (!DU) 
Total outpatients 
A!DS Total 
N (%) N (%) 
Dead 
Non AlOS 
N (%) 
AlOS 
N (%) 
Total 
N (%) 
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Table V Transmission characteristics of outpatients by disease stage and death 
status; Imam Khomeini VCT center ,2004, cont'd. 
History of 
3.2.3. First CD4 connt 
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Median first CD4 count was 329 cens/mm3 for HIV positive outpatients(table VI ) 
with a range of 3 to 1725 cens/mm3.For people with AIDS, 75% of first CD4 
levels were less than 257. Median CD4 count for those who died was 103 when 
first seen. The range of first CD4 for those who died was from 5 to 1108 cens/ 
mm3• 
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Table VI First CD4 count cells/mm3 of outpatients by disease stage and death 
status. Imam Khomeini VCT center, 2004 
Ali outpatients Dead outpatients 
Disease 
stage 
Standard 
Deviation 
NonAIDS 
N=114 
534,90 . 
270,00 
AIDS 
N=lll 
Total 
N=237 
NonAIDS 
N=3 
@ Disease stage of 2 dead and 12 total outpatients who had CD4 count was not recorded 
o Disease stage of 3 missed outpatients who had CD4 count was not recorded 
€ Disease stage of 86 outpatients is not recorded 
AIDS 
N=8 
Total 
N=13 
40 
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3.2.4. Antiretroviral therapy 
125 out of 173 outpatients (72%) in Imam Khomeini VCT center were managed 
with ART, ofwhom 90 outpatients (72 %) had AIDS (table VII). Disease stage of 
the remaining 28% was not recorded. 7 patients who had been on ART had died, 4 
ofwhom had AIDS. 
Table VII Antiretroviral therapy among AIDS outpatients by death; Imam 
Khomeini VCT center, 2004 
Ali outpatients Dead outpatients 
Disease 
AIDS Total* AIDS Total * 
Stage 
N(%) N(%) N(%) N(%) 
* Disease stage of other outpatients was unknown 
3.2.5. Outpatient use of services 
3.2.5.1. Imam Khomeini VCT 
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523 HIV negative outpatients used services at the Imam Khomeini VCT center in 
2004 for testing and counseling. If we assume 2 visits, one for first time 
consultation and a second for getting test result, then there were 1046 visits for this 
group of clients. On the other hand, 339 clients had active records as HIV positive 
patient who received treatment, care and other services in Imam Khomeini VCT 
center. The mean number of outpatient visits for these HIV positive outpatients was 
4.1 in the year 2004 which was apparently less than the other VCTs studied. The 
reason could be outpatient services provision by specia1ists in this VCT. A total of 
2436 visits had been generated by HIV positive and HIV negative clients during 
2004 in this center. 
3.2.5.2. Other VCTs 
The annual average visits per HIV positive client in the 5 other VCTs was 7 with 
the range of 4 to 12. 
In the VCTs affiliated with Kurdistan University, there were 72 new HIV positive 
cases recorded and totally 3834 annual visits. In the VCTs affiliated with Shiraz 
University, there were 132 new cases recorded and totally 1691 annual visits in 
2004. There were 343 new cases recorded and totally 8796 annual visits in the 
VCTs affiliated with Lorestan University in 2004. In the same year, In West of 
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Tehran VCT affiliated with Iran University of Medical Sciences, there were 82 new 
cases recorded in 2004 and totally 4730 annual visits .In the VCTs affiliated with 
the Kermanshah University, there were 249 new HIV positive cases recorded in 
2004 and totally 6626 annual visits (table VIII). 
3.2.6. Expenditure on outpatient services at clinics 
The financial department of Imam Khomeini VCT had spent 297 155 000 Rials for 
outpatient care in 2004. Considering 2436 visits, the cost per visit was estimated at 
114 595 Rials in 2004 in this VCT. Ifwe consider an average of 4,1 visits per HIV 
positive individual, the outpatient cost per individual per year was 468 840 Rials in 
Imam Khomeini VCT in 2004 or 36,5 US$ and 171 Int$. 
In the VCTs affiliated with Kurdistan University, total costs for outpatient care 
amounted to 770 000 million Rials in 2004. At the same year, in the VCTs 
affiliated with Shiraz University, total outpatient costs amounted to 712 400 million 
Rials.In the VCTs affiliated with Lorestan University total outpatient costs in 2004 . 
was 2 159 500 million Rials. In the West of Tehran VCT, affiliated with Iran 
University of Medical Sciences, outpatient costs amounted to 467 720 million Rials 
in 2004.In the VCTs affiliated with the Kermanshah University, total outpatient 
costs were equal to 1 100 000 million Rials in 2004(table VIII). 
1 
2 
3 
4 
5 
6 
Table VIII Outpatient VCT costs in selected Universities of Medical 
Sciences in 2004 
No of No.ofnew Estimated Total outpatient 
Outpatient outpatients total visits cost (1000 Rials) 
records (at first time 
University (new and old) visit) 
(1) (2) (3) (4) 
Kurdistan 
110 1532 3834 770 000 
Shiraz 101 492 1691 712400 
Lorestan 
502 2641 8796 :2 159 500 
Iran (West 
of Tehran 270 1576 5024 467720 
VCT) 
Tehran(Imam 339* 523 2436 279 155 Khomeini VCT) 
Kermanshah 714 814 6626 1 100000 
Average cost per visit 
* with average 4.1 visits per outpatient annually 
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Cost per 
Visit 
(Rials) 
(5) 
200835 
421289 
245509 
93097 
114595 
166013 
206889 
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3.3. HIV expenditures at the nationallevel 
\ 
3.3.1. Inpatient expenditure 
According to the Iran's Ministry of Health's Center for Disease Control, in Iran, 
until the end of 2004, 9188 HIV positive persons were known to be alive and 300 
HN positive people died during this year( Iran Ministry of Health, 2005) . 
Given 2896 HIV positive newly diagnosed in 2004, to detennine the number of the 
HIV positive infected people alive in the middle of that year (the average year 
number), half of the 2896 newly diagnosed in this year have been excluded from 
the total 9188, assuming that half of the newly diagnosed cases were detected in 
first half of the year and the second half of the cases in the second half of the year. 
Thus, in the middle of year 2004 there were an average 7740 HN positives alive 
who were assumed to receive inpatient services at the rate of 2,35%. This means 
that the number of people hospitalized in that year was estimated at 183 people. 
Also, since the records show that almost aH the HIV positive people who died 
received hospital care in the last months or days of their lives, we are required to 
add the number of 300 HN positive people deceased in this year to the 183 patients 
who were estimated to have been hospitalized by mid-2004. Therefore, it 1S 
estimated that 483 HIV positive people were hospitalized in the country in 2004. 
As the estimated inpatient cost per day was 167 661 Rials in 2004, the estimated 
inpatient cost was 4 165 730 Rials per patient per year. Therefore, for our estimated 
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483 admissions, total inpatient costs in 2004 are estimated to be 2012 million Rials 
for HIV positive patients .This amount equals 236 946 US$ or 733 753 Int$ (table 
X, page 98). 
3.3.2. Outpatient expenditure 
On average, the outpatient cost per visit provided at the 6 VCT centers studied 
amounted to 206 889 or 24,5 US$ and 75,4 Int $ in 2004 (table VIII, page 89). 
The number of HIV positive people estimated to be eligible to receive the required 
services at the middle of the year 2004 was 7890 people generating a total 94 030 
visits in all VCTs in the country. As the average cost per visit was 206 889 Rials, 
the estimated cost for outpatient services at VCTs at national level in 2004 was 
19454 million Rials (table IX, page 93). 
In 2004 Welfare Organization and Prisons Organization spent 10750 million Rials 
and Iran Red Crescent Society 5000 million Rials for outpatient HIV related care 
and treatment(Country Report on UNGASS Declaration, 2006) .In total outpatient 
services use expenditures at the outpatient clinics except for the Ministry of 
Health's VCTs accounted to 15 750 million Rials or 1 861 887 US$ and 5 743 704 
Int $ in 2004. 
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Total expenditures as outpatient services on HIV include the outpatient costs in the 
VCTs affiliated with MoH (Imam Khomeini and 5 other VCTs) extrapolated to the 
national expenditure estimations and the expenditures at clinics affiliated with other 
Ministries. They were estimated to amount to 35 204 million Rials in 2004. 
3.3.3. ART expenditure 
Antiretroviral Drugs in Iran are provided by CDC. The drugs are distributed free of 
charge at point of delivery and used in the VCTs, other outpatient clinics, and 
infectious disease wards in tertiary referral hospitals that treat HIV positive 
patients, most of which are governmental university hospitals at the centers of big 
provinces. Considering the estimated 60 000-70 000 HIV positive people in Iran, 
5% or 3000 people had been estimated to have been eligible to receive ART. In 
2004, 380 HIV positive people have received ART (Iran Ministry of Health and 
Medical Education. Islamic Republic of Iran HIV/AIDS Situation and Response 
Analysis, Dec 2006). The CDC reported a total expenditure of 7100 million Rials 
on ART in 2004(Country Report on UNGASS Declaration, 2006). Since the 
expenditure for drugs other than ART such as antibiotics and methadone are 
included in cost items for outpatient costs, they are not considered separately in our 
expenditures estimations. 
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Table IX Calculation of total outpatient expenditures in Iran in year 2004 
Label Description of variable Quantity Data 
Status 
(A) Total HIV positive people registered in the 10265 (input) 
VCTs up to the end of2004 
(B) Total death from HIV positive people registered 1077 (input) 
in the VCTs up to the end of2004 
(C) Total alive HIV positive people registered in the 9188 (A)_u(B) 
VCTs up to the end of2004 
(D) Death in HIV positive people in 2004 300 (input) 
(E) Newly registered HIV positive in 2004 2896 (input) 
(F) Number ofHIV positive people eligible to 7890 (C)+\Dl2) 
receive services at mid-2004 + (E/2) 
(G) Average annual outpatient VCT visits 7 (input) 
Per HIV positive person 
(H) Total outpatient VCT visits in Iran in 2004 55230 (F) *OO(G) 
(1) VCT clients seeking consultation and test in 2004 19400 (input) 
(J) Minimum number of visits for (1) 2 (input) 
(K) Number ofVCT visits for (1) 38800 (1) * (J) 
(L) Number ofveT visits for HIV positive and negative in 2004 94030 (H) + (K) 
(M) Average VCT visit cost in 2004 (Rials) 206889 (input) 
(N) Total outpatient expenditures in Iran in 2004 19454 million (L) * (M) 
(Rials) 
.. 
a (-): Mmus; B(+): Plus; E(/): DlVlded by; 00(*): Multlpled by 
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3.3.4. Blood testing and screening 
This service is totally conducted by Blood Transfusion ûrganization(BTû). These 
services included: 
a) Personnel training; 
b) Consulting services; 
c) Screening and HIV tests for blood donors; 
d) Research in HIV related blood services. 
Total expenditure in 2004 was reported as 45 000 million Rials. There are also 
sorne other costs for blood testing for the HIV positive people when they use 
outpatient and hospitalization services ,but these are included in cost items for these 
servIces. 
3.3.5. Public education for HIV 
The two organizations responsible for these services are the Ministry of Education 
(MûE) and the Islamic Republic of Iran Broadcasting (IRIB).In 2004, the MûE 
had a number of programs for public and students' education in public schools at 
secondary and tertiary levels. Total expenditure for these programs in that year 
accounted for 3687 million Rials which were financed totally by the head office in the 
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MûE. The IRIB also conducts education programs on HIV in the following programs: 
a) Ordinary radio health programs; 
b) Ordinary T.V. health programs; 
c) Special T.V. programs and series on HIV/AIDS; 
d) IRIB internet health programs (specifically related to HIV prevention); 
e) Training workshops for public media personnel (specifically related to HIV 
prevention). 
In 2004 the total expenditure in the above programs accounted to 2162 million 
Rials. 
3.3.6. Harm reduction activities 
These expenditures relate to harm reduction interventions including the distribution 
of sterile syringes and needles, counseling and education services, Methadone 
Maintenance Treatment (MMT), distribution of condoms and information 
brochures delivered by peers and other volunteers or out reach team at DICs or 
pharmacies based on the nature of the intervention. Expenditures related to DIC-
type interventions that were provided in VCTs (triangular clinics), Prisons' 
Organization (PO), Welfare Organ~zation (WO), and Iran Red Crescent Society 
(IRCS) are considered in this study under the topic of outpatient expenditures. 
In 2004, the expenditure on these harm reduction interventions' expenditures 
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accounted for 12 550 million Rials or 1 483 600 US$ or 4 577 000 Int $ (Country 
Report on UNGASS Declaration, 2006). 
3.3.7. Armed forces expenditure 
The armed forces spent 3 084 million Rials or 364 580 US$ and 1 125000 Int $ for 
condom procurement, and HIV control and prevention programs in their health care 
centers in 2004 (Country Report on UNGASS Declaration, 2006). 
3.4. Estimated total national HIV expenditure in 2004 
Public expenditures on HIV prevention, care, treatment, and support services were 
estimated at 108 637 million Rials or 12 841 974 US$ and 39 618 695 Int $ in Iran 
in 2004. This amount is consisted of seven main expenditure areas described ab ove 
and is shown in detail in table X, page 98. 
The following analysis provides information on sorne classifications of the HIV 
expenditures: 
a) Total expenditure in all the HIV services was estimated to be 108 637 million 
Rials. Regarding the identified 7890 HIV positive people, in 2004 the per 
capita expenditure for HIV positive people was 13 768 948 Rials, equal to 
1628 US$ and 5021 Int$. 
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b) The direct expenditures on inpatient, outpatient and ART servIces, was 
estimated at 5 616 730 Rials per capita, equal to 664 US$ or 2048 Int$. 
c) For blood testing and screening services, public education, harm reduction 
activities, and HIV control programs for armed forces per capita expenditure 
on 2896 HIV positive people, as was done in 2004, was 22 210 290 Rials. 
This is equal to 2600 US$ and 8100 Int$. 
Table XI, page 99 also shows expenditures in terms of preventive programs for: 
a. The primary prevention care, regarding HIV blood screening, and 
education, are estimated 48 687 million Rials. This constitutes 44,8 % of 
total HIV expenditures in Iran in 2004. 
b. The secondary care for the HIV positive at specialists level, following 
inpatient care or hospitalization and provision of antiretroviral therapy 
(ART) for specialists'(higher level) services is estimated at 9112 million 
Rials. This constitutes 8,4 % of total HIV expenditures in Iran in 2004. 
The expenditures in terms of foreign ex change in 2004, for prevention care type (a) 
was 5 756 000 US$ or 17 755 536 Int $, and for prevention care type (b) was 
1 076 273 US$ or 3 322 978 Int $ respectively. Regarding HIV outpatient 
expenditures which compromises both pnmary and secondary prevention, this 
amounted to 6 010 000 US$ or 18 540 OOOInt $. 
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Table X HIV expenditure sources in Iran in 2004 
International 
Expenditure Million US %from Source and 
dollars 
items Rials dollars total type of data 
(PPP) 
1- [npatient Patients' 
2012 236946 733753 1,85 
scrvlces Records 
2- Outpatient 
35204: 4161643: 12838181: 32,41: 
services: 
Records in 
2.1-VCTs 19454 2299756 7094477 17,91 
VCTs 
2.2 - Other MOH 
[5750 1 861 887 5743704 14,50 
outpatient clinics Reports 
3- ART 7100 839327 2589225 6,53 MOH Reports 
4- Blood Testing & MOH 
Screening at BTO 45000 5320000 16411 000 41,43 Reports 
5- Public 
3687: 435878: 1344536: 3,39: 
Education: 
5.1-MOE 1525 180278 556136 1,40 MOE Reports 
5.2- IRlB 2162 255600 788400 1,99 MOH Reports 
6- Hann Reduction MOH 
12550 1483600 4577 000 11,55 
Activities Reports 
7- Anned Forces' MOH 
3084 364580 1125000 2,84 
Programs Reports 
108637 1284] 974 396]8695 100,00 -
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Table XI Breakdown of total HIV expenditure in Iran in 2004 by type of 
prevention programs 
Stage of Programmes Expenditure Tnt $ (PPP) %of 
prevention total (million 
Rials) 
Primary & Outpatient 35204 12838 181 32,4 
Secondary 
Services Prevention 
Harm Reduction 12550 4577 000 11,6 
~ Activities 
Armed Forces' 3084 1 125 000 2,8 
HIV Control 
. 
Sum 50838 18540181 46,8 
Only Primary Blood Testing 45 000 16411 000 41,4 
Prevention(a) &, Screening 
Public 3687 1 344536 3,4 
Education 
Sum 48687 17755536 44,8 
Only Secondary Inpatient 2012 733753 1,9 
prevention(b ) servIces 
ART 7100 2589225 6,5 
Sum 9112 3322978 8,4 
Total Ali programmes 108637 39618695 100 
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3.5. Sensitivity analysis 
The point estimate for direct medical expenditures of HIV in 2004 amounted to 
108 637 million Rials. If we consider the lower visit schedule scenario yearly 
average of 4 outpatient visits for HIV people at each VCT, this gives an estimation of 
93 550 million Rials or Il 058 967 US$ and 34 116 000 Int$, respectively. 
If we con si der the upper visit schedule scenario with a yearly average of 12 
outpatient visits for HIV infected people at each VCT, the direct medical 
expenditures of HIV in 2004 was 172 407 million Rials. In terms of foreign 
ex change in 2004 this is 20 381 000 US$ and 62837000 Int$, respectively. 
Considering 7890 HIV positive people, the public has spent at least 1402 US$ or 
4324 Int$ and at most 2583 US$ or 7968 Int $ with the point estimate of 1628 US$ 
or 5020 Int $ per capita in 2004. 
CHAPTER4 
Discussion 
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4.1. The Iranian HIV epidemic and response 
The HIV epidemic is changing in Iran, from a low level epidemic, with no 
population group having a prevalence greater than 5%, to a concentrated epidemic. 
The epidemic is currently being driven by IDUs with more thail 60% of reported 
HIV infected people and their contacts. There has been an increase in the number 
of estimated people living with HIV in Iran, from 20 000 in 2002 to 31 000 in 
2003, and 70 000-100 000 in 2005. 
HIV health service provision in Iran, has changed over time .As the epidemic is 
changing, increasing number of people living with HIV will require the use of 
services, which will require the expansion of services.This in turn will require 
increased monitoring and evaluation of new and old services. 
The present study is part of a comprehensive study titled "Burden of HIV in Iran", 
of which this study on estimated expenditure on HIV in Iran in 2004 is the first 
phase. As has been pointed out, "information on the structure, process, outcome 
and impact of healthcare provision should be collected at many leve1s of service 
provision. This is now possible due to the enormous deve10pments in information 
technology. Such .information inc1udes activity data on the use of services, drugs 
prescribed and procedures performed, as well as the outcomes of these 
interventions. Outcomes are changes in health status of individuals attributable to 
treatments or other interventions, and inc1ude biomedical measures-c1inical or 
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other markers-as well as more subjective measures of patient wellbeing, while 
impact in this context is the outcome at the population level." (Beck et al., 2006). 
A retrospective study was designed to collect the data. We wanted to perform a 
. study to estimate the expenditure on HIV in Iran in 2004. However, relevant data 
were not readily available, neither from medical case notes nor from other sources. 
The HIV services, which we identified for this study included the following areas: 
1) Inpatient care (hospitalization); 
2) Outpatient care, treatment, testing and counseling, and education; 
3) ART provision; 
4) Blood testing and screening for prevention from HIV transmission; 
5) Education programs for the general Public and school students; 
6) Harm reduction activities; 
7) HIV control programs at armed forces' health care centers. 
We used a bottom-up approach to estimate inpatient and outpatient costs. This 
information on the cost of inpatient and outpatient care for people living with HIV 
was used as a proxy for national expenditure on these services. 
We estimated expenditures spent in the above seven areas in order to estimate total 
expenditures on HIV treatment, care, prevention, and supportive services in Iran in 
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2004. This is the tirst study, which tried to estimate expenditures on HIV infection 
in Iran. 
4.2. Study limitations 
In this study we faced with several serious limitations to obtain the relevant data. 
We gathered data regarding the use and cost of HIV health care provision from one 
inpatient center, which raises serious con cern about the representative nature of the 
information especially given the small sample size. 
In Iran, HIV patients are mostly referred to university hospitals when 
hospitalization is needed. We estimated the basic expenditures in the governmental 
sector, and excluded items like extra-costs for 'private beds in governmental 
hospitals'. We also excluded the private sector hospitals, however to date these do 
not seem to provide much inpatient HIV care. This might result in under-estimating 
inpatient expenditure.To improve our estimations, additional costing studies should 
be performed in other hospitals. 
We included all deaths that had happt:(ned in 2004 who were reported to CDC in the 
inpatient expenditure estimation. As mentioned before, given the number of 
estimated person living with HIV in Iran, it is highly likely that a large number of 
these undiagnosed people may well die at home or in hospital without their HIV-
related cause of ,death being diagnosed or recorded. If someone had died due to 
105 
HIV and not reported as such, these could not be identified and inc1uded in the 
estimation and are likely to have resulted in underestimating expenditures. 
Another point is that, as the anti retroviral drugs are distributed free of charge in the 
whole country, we assumed that aH drugs are distributed and consumed by eligible 
HIV or AIDS patients .Thus, we inc1uded ART expenditures as a separate 
expenditure area using a top down approach. 
As this was a retrospective study and the medical records were poorly maintained, 
we were confronted with a large amount of missing data re1ating to date of death, 
cause of death, laboratory examinations, disease stage, and information on 
opportunistic infections. Data were po orly recorded in patient case notes at aH the 
centers studied. This caused a lack of data regarding stage of HIV infection as well 
as poor data regarding the use and outcome of service delivery. 
In the VCTs, we also faced incomplete data recording especiaHy for different ART 
re1ated issues such as treatment duration, drug side effects, and others. We were not 
able to distinguish between expenditures on preventive services compared with 
treatment and care services. 
Another limitation to the study was that there were no robust data regarding the 
total number of HIV positive using inpatient and outpatient hospital services during 
the data gathering time. AIso, patients' inpatient and outpatient data could not be 
linked. Hence, the exact inpatient rate could not be calculated. 
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There were no data regarding perœntage of HIV positive people seeking medical 
care. AIso, the correction factor for the real number of HIV positive people in the 
country could not be determined. We did our calculation based on a selected 
number of HIV positive people in the country reported to CDC. Thus, our 
estimations regarding the HIV expenditures might be inaccurate and may 
overestimate expenditure per infected person. 
Finally, although important, we did not estimate indirect, capital, and start up costs 
in the inpatient and outpatient cost estimation because of the paucity of existing 
financial information at hea1th facility and other leve1s. Thus may underestimate 
national IP and OP expenditures. To estimate these, an in-depth costing exercise is 
required, which was weIl beyond the scope and resources of this study. 
4.3. HIV expenditures in Iran 
Despite these limitations national expenditures on HIV in Iran on inpatient care, 
outpatient care, treatment, testing and counseling, ART provision, prevention and 
education in 2004 was estimated at 108 637 million Rials or 
12 841 974 US$ and 39,6 million Int $. This was similar to that reported as part of 
Iran's UNGASS report in 2006 (Country Report on UNGASS Declaration, 2006). 
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Izazola and colleagues (2002) reported on expenditures on HIV in 5 Latin America 
countries as shown in the following tables: 
Table 1 HIV expenditure in 5 Latin America countries, 1998 
Total estimated Total HlV Distribution of the Distribution of 
national HIV expenditures total HIV the total HIV 
expenditures per capita expenditures in 
(US$) expenditures in care 
Country (million Int$) prevention 
Guatemala 29,5 0,08 15% 70% 
Uruguay 32,5 6,63 36% 51% 
Mexico 257 1,25 29% 66% 
Brazil 587,4 2,69 10% 80% 
Honduras 33,9 3,6 28% 65% 
(1999) 
Source: Izazola et al.,2002 
The share of total expenditures on antiretroviral drugs ranged from 52% in 
Guatemala to 75% in Brazil, even when the estimated coverage of antiretroviral 
therapy was close to 10% in Guatemala and universal in Brazil (Izazola 
et al., 2002). 
A study done in 2000 on HIV expenditure in 12 Latin America and Caribbean 
countries, reported that 753 million US$, or 73% of overall HIV expenditures, in 
the 12 countries were spent on treatment and care, with only 283 million US$ 
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(27%) spent on prevention. Almost 72% of the expenditure on HN care in the 12 
countries was spent on drugs, with 90% spent on ART. The authors conc1uded that 
this estimate appeared to be high and may be biased, as drug expenditures are 
easier to monitor than other components, especially when procurement of ART is 
centralized through national HIV programs such as is the case in Brazil (Opuni et 
al., 2002) 
The CUITent study, estimated that expenditures in 2004 on HIV primary prevention, 
inc1uding HIV blood screening, education for general population, outpatient care, 
harm reduction activities, and also armed forces HIV control were Il 767 670 US$ 
or 36 295 717 Int$ , which constituted 91,6% of total expenditures. If we exc1ude 
the last three expenditures, primary prevention expenditures inc1uding blood 
screening and public education drop to 5 755 660 US$ or17 755 536 int$. 
Expenditure for HIV inpatient care or hospitalization and provision of antiretroviral 
therapy (ART) was 1 077 180 US $ or 3322978 int$ in 2004 or 8,4% of total HIV 
expenditures . ART expenditure accounted for 6,5% of all HIV expenditures. Given 
the very limited data available, these figures need to be viewed with a large amount 
of suspicion. 
According to our estimation, the Iranian government sector has spent 13 772 000 
Rials (95% CI: Il 860000 to 21 850000 Rials) or 1628 US$ (95% CI: 1402 US$ 
to 2583 US$) per HIV positive person in the year 2004 in Iran. 
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We did not include the costs of private hospitals, capital, indirect costs, and 
expenses for research and higher level education .If above costing data were to be 
included, the estimation would likely to have been higher than the present one. 
These are sorne of the additional information gaps, which would need to be 
comp1eted, as weIl as better data on inpatient and outpatient services, in order to 
arrive at a more comprehensive costing study. 
4.4. Inpatient and outpatient use of services 
Only 13 HIV infected people could be identified as having been hospitalized at 
Imam Khomeini hospital in 2004. One possible reason for this could be the stigma 
regarding HIV or AIDS patients in Iran, in addition to poor medical record keeping. 
Of those few who could be identified as being seropositive, the mean 
hospitalization episode per patient was 1,23 per year, and mean inpatient days were 
24,8 per paiient-year and 20,2 days per admission. Most of these inpatients had 
AIDS. An average 4,1 outpatient visits per year was made to the Imam Khomeini 
VCT, compared with 7 visits in the other VCT sites. 
In a study set in Cape Town by Badri and colleagues (2005) for patients without 
AIDS, the mean number of inpatient days per patient year was 1,08 (95% 
confidence interval: 0,97-1,19) for the HAART group versus 3,73 (95% CI: 3,55-
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3,97) for the No-ART group. The mean number of outpatient visits per patient year 
was 8,71 (95% CI: 8,40-9,03) versus 4,35 (95% CI: 4,12-5,61) respectively 
between 1995 to 2000.For AIDS patients, mean inpatient days per patient year was 
2,04 (95% CI: 1,63-2,52) for the HAART versus 15,36 (95% CI: 13,97-16,85) for 
the No-ART group. Mean outpatient visits per patient year was 7,62 (95% CI: 
6,81-8,49) compared with 6,60 (95% CI: 5,69-7,62) respectively. 
Beck and colleagues (2004) reported that the mean number of inpatient episodes 
was 0,66 (0,19 to 1,13) for those who had AIDS from July to Dec 2000 in the UK. 
Also the mean outpatient visits for asymptomatic patients was 8,30 (95% CI: 7,18 
to 9,42) during July to Dec 2002. For AIDS patients mean outpatient visits was 
mostly 10,98 (95% CI: 9,67 to 12,29) in Jan- June 2002 period (Beck et al., 2004). 
4.5. Demographie and transmission eharaeteristies of 
inpatients and outpatients 
Regarding HIV positive outpatients in Imam Khomeini VCT center, 35,1% had 
AIDS. In the report from CDC, Iran, 3,8% (390 out of 10 265) of reported HIV 
positive people from 1987 till 2005 had AIDS (Pourmalek et al., 2005). This 
greater number of AIDS patients might be due to the greater diagnostic and 
therapeutic expertise, which is available at the Imam Khomeini Triangular Clinic 
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and VCT center.Another reason might be the inadequate data collection system in 
Triangular Clinics and VCTs. 
Regarding demographic characteristics of the HIV outpatients, 88,5% were men. 
Higher frequency of risk factors such as IDU, needle sharing in prisons, and high-
risk sexual behavior were recorded in men compared with women in Iran and could 
explain the large number of HIV infected men. Although HIV is more frequent in 
men, more women present late in their clinical course with AIDS compared with 
men: 27,8% in women compared to 18,1 % in men. Women may seek HIV testing 
less frequently and later than ,men, possibly due to lower knowledge or different 
attitudes and the existence of greater cultural or social barri ers for women to access 
HIV health care services. This underscores the greater unmet need for knowledge 
improvement and appropriate access to HIV health services for women. 
For those of known marital status 58% of HIV positives were unmarried or 
divorced: many HIV positive people are young men with unstable marital status. 
This might result in a future change in the transmission pattern of HIV from 
predominantly through injecting drug use to a predominantly sexual route. 
The number of IDUs among HIV positive persons was very high in our study 
(62,5%), which confirms other reports. HIV in Iran is thought to be circulating 
widely among drug injectors, of whom there were an estimated 200 000 in 2003 
(UNAIDS, 2006 ). Studies conducted in 2005 underscored the urgent need to 
broaden preventive programmes, especially for incarcerated drug injectors. Most of 
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the drug injectors who participated in the Tehran study were sexually active, with 
. many either buying or selling sex , while only 53% of sexually active injecting 
drug us ers had ever used a condom ( UNAIDS, 2005) 
An earlier study had found that about half of injecting-drug us ers were married, and 
one third had reported extra-marital sex which suggests a clear possibility of sexual 
transmission ofHIV from infected drug injectors to their sexual partners (UNAIDS 
2005). 
Transmission of HIV through sexual routes is more frequent in Imam Khomeini 
VCT (25,7%) compared with 6,7% in other parts of Iran (Pourmalek et al., 
2005).This might be due to changes in the transmission pattern of the virus from 
IDU to the sexual route .As Iranian culture does not allow the people to be open 
concerning extramarital sex, the actual frequency of sexual transmission route 
might be much higher. 
The frequency of transmission via blood or blood products is higher in the study 
population than reported in other areas of the country (9,1 % versus 2,1%) 
(Pourmalek et al., 2005) . From the time the first HIV positive person was infected 
through contaminated blood transfusion in 1987, it seems that preventive programs 
such as HIV screening in blood donors had been effective. But more studies are 
required to prove this. 
History of imprisonment is relatively high in the clients to Imam Khomeini VCT 
(58,4%) .In general, imprisonment and injecting drug use appeared to be the 
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biggest risk factor for HIV infection in Iran. The reason is that many people in 
prisons inject drugs (UNAIDS 2005).According to reports by the National AIDS 
program, HIV rates among prisoners rose six times in 1999 compared to 1996 
(UNAIDS 2005). 
4.6. Recommendations 
These recommendations are made based on the experience of the writer obtained 
during the study, a pro cess which included reviewing the literature, data gathering 
and analysis. While sorne of the recommendations go beyond the direct scope of 
the thesis, they are certainly pertinent for future researchers, who want to work in 
this area, and those healthcare professionals and other stakeholders who want to 
improve the effectiveness, efficiency, equity and acceptability of monitoring and 
evaluating the Iranian response to their HIV epidemic. 
1. It is needed to plan, implement, manage and evaluate, the HIV 
epidemic in Iran according to the Iranian culture, socioeconomic 
status, health services infrastructure, budget, and aIl other elements 
that constitute Iran's context. 
2. Health services play a critical role in HIV prevention, treatment, care, 
and support services provision. Fortunately, in Iran, the Primary 
Health Care network was started in 1985 and much experience exist 
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regarding health servIce delivery to all levels of the Iranian 
population. Although service delivery to HIV positive and HIV 
negative population needs its own services because of the nature of 
infection, its transmission routes, the characteristics of the infected 
people, stigmatism, drug prices, and other pertinent issues, the policy 
makers could draw valuable lessons from the experiences obtained 
from the development of the Primary Health Care network. 
3. Iran should develop and adopt a minimum clinical data set, which 
should be collected longitudinally on patients to ensure good patient 
management, which should also include socio-economic data. 
Clinical and socio-economic minimal data sets have been defined by 
country and international experts and could form the basis of 
developing Iran-based data sets (HIV Patient ART Monitoring 
Meeting, Geneva , 2004 and , WHO/TDR Generic Tools Workshop 
Report, 2006). Also transmission pattern of HIV should be tracked 
and any changes in the pattern detected to be analyzed. 
4. Hospitals and clinics need to develop and adopt good medical record 
systems if not already in place. These can be paper-based or 
electroilic in nature. The data need to be collected longitudinally on 
the use and outcome of services by individual patients, to ensure good 
clinical management. 
5. When these are established, multi-centre prospective monitoring and 
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evaluation systems can be set up across different units, extending 
across primary, secondary and tertiary centers. This should be part of 
tracking the response to the epidemic. 
6. In terms of HIV service delivery, the lack of a well defined 
monitoring and evaluation system is evident. Staffs, especially in the 
peripheral sites are not aware of the importance of data collection and 
active follow up. Capacity building in this regard seems essential. 
Staff education, putting in appropriate incentives, and regular 
monitoring could be among possible solutions. 
7. As demonstrated, there are different areas of HIV expenditure in Iran, 
including on public education, through the Islamic Republic of Iran 
Broadcasting agency and Ministry of Education. HIV educational 
programs In prisons, NGOs, or other agencies might also be 
supported by national funds. The proportion of ex.penditure in each 
agency on the preventive, supportive, care, and treatment should be 
clarified annually. This would allow better decisions to be made on 
resource allocation and planning in respective areas. 
8. As recently pointed out, "Many have welcomed the recent 
momentum to provide HIV -infected people in middle- and lower-
income countries with appropriate treatment and care, including 
ART. However, if HIV incidence levels are not reduced, the 
increasing number of new people infected with HIV, combined with 
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fewer people dying from HIV due to ART, will result in more HIV-
infected people alive and requiring medical and social services. Apart 
from humanitarian considerations, increased requirement for HIV 
services can lead to significant cost increases, as has recently been 
seen in the us and the UK" ( Beck et al., 2006) .We estimated that 
6,5% of total HIV expenditures at the national level are allocated to 
ART in 2004. The effectiveness, efficiency, equity, and acceptability 
ofthis intervention in Iran need to be fully investigated. 
9. To comply with the research projects needed in HIV area in Iran, the 
design and implementation of a research strategy could be very 
beneficial and help in priority setting of the research topics.This may 
prevent resource wastage and duplication. A strategy or map helps to 
find the way to where you want to go. A research map will also help 
to find the way to where you want to go with your research (Research 
Helper, n.d). 
10. In this regard, doing a full and formaI costing study at a national 
level, guided by the results of the present costing exercise, with a 
micro-costing approach and longitudinal design seems to be a 
priority. 
Il. Information on the use, outcome, and impact of interventions or 
programs needs to be complemented by doing costing studies in 
different types of hospitals on a regular basis to collect robust and 
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contemporary cost information. 
12. Sorne individu al level information can also be used for program or 
service monitoring & evaluation at primary, secondary & tertiary 
facilities. These data can then be reported to a central site, like CDC, 
when the relevant analyses can be performed to obtain the following 
data: 
• The mean inpatient episodes per patient year by disease 
stage. 
• The mean outpatient visits per patient year by disease 
stage. 
• The average cost ofhospital services per patient year. 
• Mean new HIV re1ated opportunistic infections per 1000 
patient year. 
• Death rate by disease stage. 
• Deaths causes and places. 
Regular feedback of these analyses needs to be provided to those 
which provide the data for analyses. 
13. Ideally, estimates of resource needs should go a step further and be 
limited to the benefits provided by the resources spent. We need to 
regularly compare 'how much is needed' with 'what is spent' and 
'what is the outcome and impact'. 
14. More community involvement is needed. Educational programs 
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should be adapted with the community needs in different age groups 
and socioeconomic level. 
15. Systems should also be developed to track expenditures from central 
level to c1inics and ideally also inc1ude other HIV -related 
expenditures. As stated: "Every country will need to address how 
HIV preventive and therapeutic services are funded, and what will be 
appropriate expenditures for these services. Countries will have to 
look c10sely at the best financial arrangements for them to ensure that 
HIV service provision free-at-the-point-of-delivery is sustainable in 
the longer term. This will requite making good use of available 
resources" (Beek et al., 2006). 
4.7. Conclusion 
In spite of aIl efforts by the Iran government in response to HIV epidemic, the 
incidence and prevalence of people living with HIV is increasing. A general 
mobilization is needed to combat this epidemic. More effective, efficient, equitable, 
and acceptable prevention, treatment, care, and support services should be 
implemented. More intersectoral collaborations, community involvements and 
research in the pertinent areas are needed. More resources should be allocated to 
this inc1uding those required to develop and improve a national multisectoral 
monitoring and evaluation system to track the response. 
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1.1. Objective 
To determine the validity and reliability of data abstraction forms. 
1.2. Methods 
Using expert opinion, we determined the face and content validity of data 
abstraction forms as compared to the patient records through a group interview and 
consultation session. The expert group consisted of one infectious disease 
specialist, two epidemiologists, one health economist, and one physician. 
After completion of the validity sub-study, a subsample of patient records inc1uding 
20 records was abstracted into study' s record abstraction form by two research 
assistants separately for assessment of concurrent reliability. These records were 
randomly chosen from aIl records in the West of Tehran VCT. It was planned for 
the same two persons to abstract patient records in the other centers in the study, 
and there were no factors violating the assumption that the reliability of their 
abstraction performance will be different in other centers in the study. For 
assessment of test-retest reliability, two weeks later, the same two persons 
abstracted the same subsample of patient records again. Inter-rater (concurrent) and 
intra-rater (test-retest) reliability were assessed by calculating the Kappa and Intra-
Cluster Correlation (ICC) coefficients for a selected number of qualitative and 
quantitative key variables respectively. 
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1.3. Results 
1.3.1. Reliability of data gathering tools 
Tables 1 to V show the result of reliability sub-study. 
Table 1 Intraclass Correlation Coefficients for "age"Two-Way Mixed Efects Model 
(Consistency Definition) 
Measure ICC 95%CLs F p 
Value LCL UCL 
Single Rater .9615 .9247 .9832 100.8267 .0000 
Average of Raters* .9901 .9801 .9958 100.8267 .0000 
Degrees of freedom for F -tests are 18 and 54. Test Value = 0 
* Assumes absence of People-Rater interaction 
Alpha = .9901 Standardized item alpha = .9901 
Table II Intrac1ass Correlation Coefficients for "CD4 count" 
Two-Way Mixed Effects Model (Consistency Definition) 
Measure ICC 95%CLs F p 
Value LCL UCL 
Single Rater .9034 .7947 .9653 ·38.3904 .0000 
Average of Raters * .9740 .9393 .9911 38.3904 .0000 
Degrees offreedom for F-tests are 12 and 36. Test Value = o. 
* Assumes absence of People-Rater interaction 
Alpha = .9740 Standardized item alpha = .9746 
Table III Intrac1ass Correlation Coefficients for "time since diagnosis" 
Two-Way Mixed Effects Model (Consistency Definition) 
Measure ICC 95%CLs F p 
Value LCL UCL 
Single Rater 1.0000 1.0000 1.0000 
Average of Raters* 1.0000 1.0000 1.0000 
Degrees of freedom for F -tests are 17 and . Test Value = o. 
* Assumes absence of People-Rater interaction 
Alpha = 1.0000 Standardized item alpha = 1.0000 
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Cohen's Kappa coefficient was one for Intrarater measurements of the variable sex 
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(within rater 1 in both tries, and within rater 2 in both tries), and for its Interrater 
measurements (between rater 1 and rater 2, in both tries), with a p-value of 0.001. 
Table IV Cohen's Kappa coefficient for four measurements of the "sex" 
Rater 
TryNo. Raterl Rater2 
Test 1 1 
Retest 1 1 
For the variable "entry into AIDS stage", there was only one patient with a positive 
value, recorded in aIl four measurements as the same. 
Intraclass Correlation Coefficients for variable "history of risk factors" was not 
calculable due to invariance of aIl four set of responses. This is interpretable as an 
ICC equal to one. 
1.3.2. Completeness of data for selected key variables 
As a sample of records and variables, the four sets of patient record abstractions 
plus data entries, as compared with the original patient records, revealed a 
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consistent pattern of data incompleteness in the original patient records, except for 
one of the patients CD4 level which was documented in the original patient 
records, but not transcripted into the data abstraction form (study questionnaire) by 
one of the raters in try 2 (post-test), and hence not present in the resultant file. 
Table V Number ofmissing data (records) for selected key variables in 20 
randomly chosen original patient records 
Variable name Number of missing data 
In original patient records 
Age 1 
CD4 count 7 
time since diagnosis 2 
Sex 0 
entry into AIDS stage 0 
. 
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Tehran University of Medical Sciences 
Questionnaire for study:" Public Expenditures on HIV Prevention, 
Treatment, Care, and Support Services in Iran, 2004" 
(A)Data Abstraction Form for Inpatient and Outpatients 
(1) Identification Code: 
(3) Status in data gathering time: 
(4) Date ofreport (dd / mm! yyyy): 
(2) Date (dd / mm! yyyy): 
01 Alive o 2 Dead 0 9 not recorded 
Please fill out sections 1&2 for both outpatints and inpatients 
1. Socio Demographie Information: 
(1) Name and sumame: 
(2) Date ofbirth (dd / mm! yyyy): 
(3) Sex: 0 1 Male 0 2 Female 09 not recorded 
(4) Marital status: 0 1 Married 0 2 Single 0 3 Separated 
o 4 DivorcedlWidowed 0 9 not recorded 
(5) Address: 
(6) Contact phone No: 09 not recorded 
2. Past history Information: 
--- History of exposure to the following risk factors (9 = not recorded): 
(1) Imprisonment history: 0 1 Yes 0 2 No 
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(2) Blood Iblood products transfusion: o 2 No 
(3) Injection drug use: o \Yes 
(4) Unsafe sexual contact: 0 \ Yes O 2 No 
(5) Delivery from infected mother: 0 \ Yes 0 2 No 
(6) HIV stage: 
(7) History of antiretroviral therapy: o \Yes O 2 No 
(8) Ifyes, date of initiation (dd/mmlyyyy):· 
(9) If yes, totals duration: months 
(10) First CD4 level: 
Please fill out this section for Imam Khomeini Triangular clinicNCT only 
(1) Refered to hospit1: 0 \ Yes 02 No o 9 not recorded 
(2) Ifyes, date of referaI (dd/mmlyyyy): 
(3) Hospital name: 
Please fill out again if the client is hospitalized more than once in 2004 (inc1uding 
date and place): 
Please fill out this section for Imam Khomeini Infectious Disease Ward 
inpatients 
(1) Time ofhospitalization in 2004: 
(2) Total number ofinpatient episodes in 2004: 
(3) Hospitalization expenditure on discharge (Rials): 
Please fill out this section in the Triangualr clinicNCT center (aIl data are 
related to year 2004) 
(1) Reporting centre: 
(2) Affiliated university: 
(3) No of outpatient records (new and old): 
(4) Number ofnew registered outpatients: 
(5) Mean No of outpatient visits: 
(6) Total cost (in Rials): 
(B)Form for collection of tinancial data available from 
organizations 
(1) Name of organization: 
(2) Date of information retrieval: 
(3) Name ofperson authorizing the information: 
(4) Position ofperson authorizing the information: 
(5) Time period for tinancial information reported: 
(6) Total expenditure in Rials: 
(7) Breakdown of expenditure by type and year( if available): 
Type Type Type Type 
Year 
( ) ( ) ( ) ( ) 
Total 
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